

Divergent Synthesis of 5- and 4-(2,1-Azaborine) Substituted Isoxazoles via Regioselective [3+2] Cycloadditions of Nitrile Oxides and B-Ethynyl-1,2-Azaborines

Yong He,^a Hao Wang,^a Yao Zhou,^b Kai Yang*,^a Qiuling Song*^{a,c,d}

^aKey Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry at Fuzhou University, Fuzhou, Fujian, 350108 (China).

^bHubei Key Laboratory of Pollutant Analysis & Reuse Technology, College of Chemistry and Chemical Engineering, Hubei Normal University, Huangshi 435002, (China).

^cInstitute of Next Generation Matter Transformation, College of Materials Science Engineering at Huaqiao University 668 Jimei Boulevard, Xiamen, Fujian, 361021 (China).

^dSchool of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan, 453007 (China).

E-mail: kyang@fzu.edu.cn, qsong@hqu.edu.cn.


Contents

1. General Information	2
2. Synthesis of B-ethynyl-2,1-borazaronaphthalene.....	2
3. Synthesis of oxime chlorides.....	7
4. General procedure for the regioselective [3+2] cycloadditions Reaction	12
5. Synthetic transformations	27
6. Crystal structure of compound 3a and 4i.....	30
7. References.....	33
8. NMR Spectra.....	34

1. General Information


Unless otherwise noted, materials obtained from commercial suppliers were used without further purification. Flash column chromatography was performed over silica gel (200-300 mesh). ^1H NMR and ^{13}C NMR spectra were recorded at ambient temperature using Bruker 400M and JEOL 500M spectrometers, chemical shifts (in ppm) were referenced to CDCl_3 ($\delta = 7.26$ ppm) and $\text{DMSO}-d_6$ ($\delta = 2.50$ ppm) as internal standards. ^{13}C NMR spectra were obtained by using the same NMR spectrometers and were calibrated with CDCl_3 ($\delta = 77.0$ ppm) and $\text{DMSO}-d_6$ ($\delta = 39.5$ ppm). Data for ^1H NMR are recorded as following abbreviations: multiplicity (s = singlet, d = doublet, t = triplet, q = quarter, m = multiplet), coupling constant (J , Hz). High resolution mass spectroscopy (HRMS) analysis was performed at an Exactive Plus (Thermo Scientific) or Agilent 8890-7250.

2. Synthesis of B-ethynyl-2,1-borazaronaphthalene



By analogy to a modified literature procedure¹, substituted vinylaniline (5 mmol, 1.0 equiv) was dissolved in 10 mL anhydrous toluene in a Schlenk flask. Borontrichloride solution (1.0 M in toluene; 10 mL, 10 mmol, 2.0 equiv) was added dropwise via syringe to the vigorously stirring solution of amine in toluene. At the conclusion of the addition, the reaction mixture was heated at reflux for 18 h. At the end of the reaction, volatiles were removed under reduced pressure to afford the corresponding B-Cl intermediate 2-chloro-1-aza-2-boranaphthalene as an air- and moisture-sensitive oil, which could be used as is in the next step without further purification. To the Schlenk flask containing the 2-chloro-2,1-borazaronaphthalene was added 10 mL anhydrous THF and the resulting solution was cooled to -30 °C. The ethynylmagnesium bromide solution (0.5 M in THF; 30 mL, 15 mmol, 3.0 equiv) was added dropwise using a syringe, and then the reaction mixture was allowed to warm to room temperature and stirred for 12 h. At the end of the reaction, the mixture was concentrated under reduced pressure, and the remaining residue was purified by flash column chromatography (petroleum ether and ethyl acetate) to afford the corresponding B-ethynyl-2,1-borazaronaphthalene **1a-1n**.

2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (**1a**)




The general procedure was followed by using 2-vinylaniline (5 mmol) to afford the desired product **1a** (85%) as a white solid (mp: $66-68$ °C). $R_f = 0.6$ (silica gel, PE:EtOAc = 20:1).

^1H NMR (500 MHz, CDCl_3) δ 8.20 (s, 1H), 8.11 (d, $J = 11.4$ Hz, 1H), 7.67 (dd, $J = 7.7, 1.4$ Hz, 1H), 7.53 – 7.42 (m, 1H), 7.30 – 7.22 (m, 2H), 6.97 (dd, $J = 11.4, 1.8$ Hz, 1H), 2.96 (s, H). ^{13}C NMR (126 MHz, CDCl_3) δ 145.6, 139.3, 129.4, 128.6, 125.3, 121.6, 118.0, 93.1. ^{11}B NMR (160 MHz, CDCl_3) δ 25.1 (s).

HRMS (EI) calcd for $\text{C}_{10}\text{H}_8\text{BN}$: 153.0750, found: 153.0743


2-ethynyl-6-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1b)



The general procedure was followed by using 4-fluoro-2-vinylaniline (5 mmol) to afford the desired product **1b** (71%) as a white solid (mp: 66-68 °C). $R_f = 0.5$ (silica gel, PE:EtOAc = 20:1).

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.17 (s, 1H), 7.99 (d, $J = 11.5$ Hz, 1H), 7.30 (dd, $J = 8.9, 2.4$ Hz, 1H), 7.24 – 7.15 (m, 2H), 7.03 – 6.90 (m, 1H), 2.92 (s, 1H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 157.4 (d, $J = 240.2$ Hz), 144.7 (d, $J = 3.3$ Hz), 135.8, 131.2, 125.8 (d, $J = 8.3$ Hz), 119.2 (d, $J = 8.5$ Hz), 116.8 (d, $J = 24.7$ Hz), 113.8 (d, $J = 21.7$ Hz), 93.3. $^{11}\text{B NMR}$ (160 MHz, CDCl_3) δ 24.9 (s). $^{19}\text{F NMR}$ (471 MHz, CDCl_3) δ -121.23 (s). **HRMS (EI)** calcd for $\text{C}_{10}\text{H}_7\text{BFN}$: 171.0656, found: 171.0657


2-ethynyl-6-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1c)



The general procedure was followed by using 4-methyl-2-vinylaniline (5 mmol) to afford the desired product **1c** (45%) as a white solid (mp: 66-68 °C). $R_f = 0.5$ (silica gel, PE:EtOAc = 20:1).

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.14 (s, 1H), 8.02 (d, $J = 11.5$ Hz, 1H), 7.43 (d, $J = 1.8$ Hz, 1H), 7.27 (dd, $J = 8.0, 2.2$ Hz, 1H), 7.16 (d, $J = 8.2$ Hz, 1H), 6.92 (dd, $J = 11.4, 1.9$ Hz, 1H), 2.92 (s, 1H), 2.44 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 145.3, 137.4, 130.9, 130.0, 129.1, 125.3, 117.8, 92.8, 20.8. $^{11}\text{B NMR}$ (160 MHz, CDCl_3) δ 24.9 (s). **HRMS (EI)** calcd for $\text{C}_{11}\text{H}_{10}\text{BN}$: 167.0906, found: 167.0903


2-ethynyl-5-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1d)



The general procedure was followed by using 3-methyl-2-vinylaniline (5 mmol) to afford the desired product **1d** (60%) as a colorless oil. $R_f = 0.5$ (silica gel, PE:EtOAc = 20:1).

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.35 (d, $J = 11.7$ Hz, 1H), 8.208.14 (s, 1H), 7.33 (dd, $J = 8.2, 7.3$ Hz, 1H), 7.12 (d, $J = 8.2$ Hz, 1H), 7.08 – 7.03 (m, 1H), 6.98 (dd, $J = 11.7, 2.0$ Hz, 1H), 2.948.14 (s, 1H), 2.628.14 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 141.8, 139.8, 136.5, 128.4, 124.1, 123.4, 116.8, 93.2, 19.6. $^{11}\text{B NMR}$ (160 MHz, CDCl_3) δ 22.6 (s). **HRMS (EI)** calcd for $\text{C}_{11}\text{H}_{10}\text{BN}$: 167.0906, found: 167.0906

6-chloro-2-ethynyl-8-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1e)




The general procedure was followed by using 4-chloro-2-fluoro-6-vinylaniline (5 mmol) to afford the desired product **1e** (74%) as a white solid (mp: 106-108 °C). $R_f = 0.4$ (silica gel, PE:EtOAc = 20:1).

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.38 (s, 1H), 7.95 (dd, $J = 11.7, 1.8$ Hz, 1H), 7.40 (d, $J = 1.7$ Hz, 1H), 7.23 (dd, $J = 10.3, 2.1$ Hz, 1H), 7.03 (dd, $J = 11.5, 1.9$ Hz, 1H), 2.96 (s, 1H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ

151.0 (d, $J = 247.5$ Hz), 143.6 (d, $J = 3.0$ Hz), 127.2 (d, $J = 3.8$ Hz), 127.1 (d, $J = 12.6$ Hz), 125.5 (d, $J = 10.3$ Hz), 123.9 (d, $J = 3.6$ Hz), 114.1 (d, $J = 21.2$ Hz), 94.0. **^{11}B NMR (160 MHz, CDCl_3)** δ 25.2 (s). **^{19}F NMR (471 MHz, CDCl_3)** δ -133.52 (s). **HRMS (EI)** calcd for $\text{C}_{10}\text{H}_6\text{BClFN}$: 205.0266, found: 205.0273


2-ethynyl-6-methoxy-1,2-dihydrobenzo[e][1,2]azaborinine (1f)



The general procedure was followed by using 4-methoxy-2-vinylaniline (5 mmol) to afford the desired product **1f** (44%) as a white solid (mp: 105-107 °C). $R_f = 0.3$ (silica gel, PE:EtOAc = 20:1).

^1H NMR NMR (500 MHz, CDCl_3) δ 8.14 (s, 1H), 8.01 (d, $J = 11.4$ Hz, 1H), 7.17 (d, $J = 8.7$ Hz, 1H), 7.12 – 7.03 (m, 2H), 6.94 (dd, $J = 11.5, 1.9$ Hz, 1H), 3.86 (s, 3H), 2.90 (s, 1H). **^{13}C NMR (126 MHz, CDCl_3)** δ 154.1, 145.0, 134.1, 130.4, 125.8, 119.0, 118.1, 110.3, 92.8, 55.5. **^{11}B NMR (160 MHz, CDCl_3)** δ 22.2 (s). **HRMS (EI)** calcd for $\text{C}_{11}\text{H}_{10}\text{BNO}$: 183.0855, found: 183.0859

2-ethynyl-7-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1g)




The general procedure was followed by using 5-fluoro-2-vinylaniline (5 mmol) to afford the desired product **1g** (54%) as a white solid (mp: 51-52 °C). $R_f = 0.5$ (silica gel, PE:EtOAc = 20:1).

^1H NMR NMR (500 MHz, CDCl_3) δ 8.15 (s, 1H), 8.03 (d, $J = 11.4$ Hz, 1H), 7.59 (dd, $J = 8.6, 6.0$ Hz, 1H), 7.04 – 6.91 (m, 2H), 6.87 (dd, $J = 11.4, 2.0$ Hz, 1H), 2.94 (s, 1H). **^{13}C NMR (126 MHz, CDCl_3)** δ 162.6 (d, $J = 247.7$ Hz), 145.1, 140.5 (d, $J = 10.9$ Hz), 131.2 (d, $J = 10.2$ Hz), 122.1, 110.1 (d, $J = 23.0$ Hz), 103.8 (d, $J = 23.7$ Hz), 93.7. **^{11}B NMR (160 MHz, CDCl_3)** δ 25.5 (s). **^{19}F NMR (471 MHz, CDCl_3)** δ -111.05 (s).

HRMS (EI) calcd for $\text{C}_{10}\text{H}_7\text{BFN}$: 171.0656, found: 171.0663


6-chloro-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1h)



The general procedure was followed by using 4-chloro-2-vinylaniline (5 mmol) to afford the desired product **1h** (65%) as a white solid (mp: 113-115 °C). $R_f = 0.4$ (silica gel, PE:EtOAc = 20:1).

^1H NMR NMR (500 MHz, CDCl_3) δ 8.15 (s, 1H), 7.96 (d, $J = 11.4$ Hz, 1H), 7.60 (d, $J = 2.3$ Hz, 1H), 7.38 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.18 (d, $J = 8.6$ Hz, 1H), 6.97 (dd, $J = 11.5, 1.9$ Hz, 1H), 2.94 (s, 1H). **^{13}C NMR (126 MHz, CDCl_3)** δ 144.4, 137.7, 128.7, 128.4, 126.6, 126.1, 119.2, 93.7. **^{11}B NMR (160 MHz, CDCl_3)** δ 25.2 (s). **HRMS (EI)** calcd for $\text{C}_{10}\text{H}_7\text{BClN}$: 187.0360, found: 187.0362


2-ethynyl-6-(trifluoromethoxy)-1,2-dihydrobenzo[e][1,2]azaborinine (1i)



The general procedure was followed by using 4-trifluoromethoxy-2-vinylaniline (5 mmol) to afford the desired product **1i** (54%) as a white solid (mp: 38-39 °C). $R_f = 0.3$ (silica gel, PE:EtOAc = 20:1).

¹H NMR NMR (500 MHz, CDCl₃) δ 8.21 (s, 1H), 8.02 (d, *J* = 11.5 Hz, 1H), 7.49 (d, *J* = 2.5 Hz, 1H), 7.34 – 7.29 (m, 1H), 7.26 (d, *J* = 8.9 Hz, 1H), 7.00 (dd, *J* = 11.5, 1.8 Hz, 1H), 2.94 (s, 1H). **¹³C NMR (126 MHz, CDCl₃)** δ 144.8, 143.2, 137.8, 125.6, 122.1, 121.1, 120.6 (q, *J* = 257.0 Hz), 119.2, 93.7. **¹¹B NMR (160 MHz, CDCl₃)** δ 25.3 (s). **¹⁹F NMR (471 MHz, CDCl₃)** δ -58.04 (s). **HRMS (EI)** calcd for C₁₁H₇BF₃NO: 237.0573, found: 237.0570


2-ethynyl-4-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1j)



The general procedure was followed by using 2-isopropenylaniline (5 mmol) to afford the desired product **1j** (65%) as a white solid (mp: 66-68 °C). *R_f* = 0.6 (silica gel, PE:EtOAc = 20:1).

¹H NMR NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H), 7.83 (dt, *J* = 8.6, 1.1 Hz, 1H), 7.48 – 7.43 (m, 1H), 7.28 – 7.22 (m, 2H), 6.78 (t, *J* = 1.6 Hz, 1H), 2.91 (s, 1H), 2.61 (d, *J* = 1.2 Hz, 3H). **¹³C NMR (126 MHz, CDCl₃)** δ 152.2, 139.7, 128.3, 125.7, 125.5, 121.5, 118.6, 92.6, 22.7. **¹¹B NMR (160 MHz, CDCl₃)** δ 22.6 (s). **HRMS (EI)** calcd for C₁₀H₈BN: 167.0906, found: 167.0911


6-bromo-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1k)



The general procedure was followed by using 4-bromo-2-vinylaniline (5 mmol) to afford the desired product **1k** (37%) as a white solid (mp: 122-123 °C). *R_f* = 0.5 (silica gel, PE:EtOAc = 20:1).

¹H NMR NMR (500 MHz, CDCl₃) δ 8.14 (s, 1H), 7.95 (d, *J* = 11.5 Hz, 1H), 7.76 (d, *J* = 2.3 Hz, 1H), 7.50 (dd, *J* = 8.6, 2.2 Hz, 1H), 7.13 (d, *J* = 8.6 Hz, 1H), 6.96 (dd, *J* = 11.5, 2.0 Hz, 1H), 2.94 (s, 1H). **¹³C NMR (126 MHz, CDCl₃)** δ 144.3, 138.0, 131.5, 131.3, 126.7, 119.5, 114.0, 93.6. **¹¹B NMR (160 MHz, CDCl₃)** δ 23.0 (s). **HRMS (EI)** calcd for C₁₀H₇BBrN: 230.9855, found: 230.9846


2-ethynyl-4-phenyl-1,2-dihydrobenzo[e][1,2]azaborinine (1l)



The general procedure was followed by using 2-(1-phenylvinyl)aniline (5 mmol) to afford the desired product **1l** (53%) as a white solid (mp: 90-92 °C). *R_f* = 0.4 (silica gel, PE:EtOAc = 20:1).


¹H NMR NMR (500 MHz, CDCl₃) δ 8.22 (s, 1H), 7.65 – 7.61 (m, 1H), 7.50 – 7.40 (m, 6H), 7.32 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.17 – 7.11 (m, 1H), 6.87 (d, *J* = 1.9 Hz, 1H), 2.93 (s, 1H). **¹³C NMR (126 MHz, CDCl₃)** 156.9, 141.9, 140.0, 128.9, 128.5, 128.2, 128.1, 127.5, 124.5, 121.5, 118.5, 93.0. **¹¹B NMR (160 MHz, CDCl₃)** δ 22.8 (s). **HRMS (EI)** calcd for C₁₆H₁₂BN: 229.1063, found: 229.1058

2-ethynyl-1-isopropyl-1,2-dihydrobenzo[e][1,2]azaborinine (**1m**)



The general procedure was followed by using N-isopropyl-2-vinylaniline (5 mmol) to afford the desired product **1m** (65%) as a colorless oil. $R_f = 0.5$ (silica gel, PE:EtOAc = 20:1). **$^1\text{H NMR NMR}$ (500 MHz, CDCl_3)** δ 7.98 (d, $J = 11.3$ Hz, 1H), 7.94 – 7.73 (m, 1H), 7.69 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.51 (t, $J = 7.8$ Hz, 1H), 7.23 (t, $J = 7.4$ Hz, 1H), 6.99 (d, $J = 11.3$ Hz, 1H), 5.36 (d, $J = 362.2$ Hz, 1H), 3.24 (s, 1H), 1.78 (d, $J = 7.3$ Hz, 6H). **$^{13}\text{C NMR}$ (126 MHz, CDCl_3)** δ 144.9, 130.9, 127.6, 120.7, 118.4, 114.2, 99.0, 96.1, 53.8, 49.6, 23.0, 21.6. **$^{11}\text{B NMR}$ (160 MHz, CDCl_3)** δ 22.5 (s). **HRMS (EI)** calcd for $\text{C}_{13}\text{H}_{14}\text{BN}$: 195.1219, found: 195.1213


1-benzyl-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (**1n**)



The general procedure was followed by using N-benzyl-2-vinylaniline (5 mmol) to afford the desired product **1n** (65%) as a white solid (mp: 75– 76 °C). $R_f = 0.5$ (silica gel, PE:EtOAc = 20:1).

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.09 (d, $J = 11.4$ Hz, 1H), 7.68 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.42 – 7.35 (m, 2H), 7.31 (dd, $J = 8.2, 6.8$ Hz, 2H), 7.27 – 7.17 (m, 4H), 7.07 (d, $J = 11.4$ Hz, 1H), 5.68 (s, 2H), 3.07 (s, 1H). **$^{13}\text{C NMR}$ (126 MHz, CDCl_3)** δ 145.6, 140.8, 138.2, 130.3, 128.7, 128.6, 127.1, 127.0, 126.0, 121.3, 116.4, 96.0, 53.56. **$^{11}\text{B NMR}$ (160 MHz, CDCl_3)** δ 24.9 (s). **HRMS (EI)** calcd for $\text{C}_{17}\text{H}_{14}\text{BN}$: 243.1219, found: 243.1228

2-(hex-1-yn-1-yl)-1,2-dihydrobenzo[e][1,2]azaborinine (**1o**)




By analogy to a modified literature procedure¹, o-vinylaniline (5 mmol, 1.0 equiv) was dissolved in 10 mL anhydrous toluene in a Schlenk flask. Borontrichloride solution (1.0 M in toluene; 10 mL, 10 mmol, 2.0 equiv) was added dropwise via syringe to the vigorously stirring solution of amine in toluene. At the conclusion of the addition, the reaction mixture was heated at reflux for 18 h. At the end of the reaction, volatiles were removed under reduced pressure to afford the corresponding B–Cl intermediate 2-chloro-1-aza-2-boranaphthalene as an air- and moisture-sensitive oil, which could be used as is in the next step without further purification. To the Schlenk flask containing the 2-chloro-2,1-borazonaphthalene was added 10 mL anhydrous THF and the resulting solution was cooled to -78 °C. The hexynyllithium (6.5 mmol, 1.3 equiv), prepared from hexyne and *n*-butyllithium, was added dropwise using a syringe, and then the reaction mixture was allowed to warm to room temperature and stirred for 12 h. At the end of the reaction, the mixture was concentrated under reduced pressure, and the remaining residue was purified by flash column chromatography (petroleum ether and ethyl acetate) to afford the desired product **1o** (50%) as a colorless oil. $R_f = 0.5$ (silica gel, PE:EtOAc = 20:1).

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.04 (d, $J = 11.4$ Hz, 2H), 7.62 (dd, $J = 7.8, 1.4$ Hz, 1H), 7.45 – 7.38 (m, 1H), 7.24 – 7.13 (m, 2H), 6.92 (dd, $J = 11.5, 1.9$ Hz, 1H), 2.44 (t, $J = 7.1$ Hz, 2H), 1.68 – 1.60 (m, 2H), 1.58 –

1.49 (m, 2H), 0.99 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 145.0, 139.7, 129.3, 128.3, 125.2, 121.1, 117.8, 107.9, 30.8, 22.0, 19.7, 13.6. ^{11}B NMR (160 MHz, CDCl_3) δ 25.4 (s). HRMS (EI) calcd for $\text{C}_{14}\text{H}_{16}\text{BN}$: 209.1376, found: 209.1373


6-ethynyl-5,6-dihydrodibenzo[*c,e*][1,2]azaborinine (5)



By analogy to a modified literature procedure,^{1,2} to the stirring solution of 2-aminodiphenyl (5 mmol, 1 equiv) in 10 mL dry CH_2Cl_2 at 0 °C was added BBr_3 (1.0M in CH_2Cl_2 , 3 equiv) drop-wise under argon atmosphere. Then the solution was warmed to room temperature and then stirred at 45 °C for 12 h. At the conclusion of the reaction, volatiles were removed under reduced pressure to afford the corresponding B–Br intermediate as an air- and moisture-sensitive oil, which could be used as is in the next step without further purification. The mixture was concentrated under reduced pressure and reused argon protection. To the Schlenk flask containing the B–Br intermediate was added 10 mL anhydrous THF and the resulting solution was cooled to -30 °C. The ethynylmagnesium bromide solution (0.5 M in THF; 30 mL, 15 mmol, 3.0 equiv) was added dropwise using a syringe, and then the reaction mixture was allowed to warm to room temperature and stirred for 12 h. At the end of the reaction, the mixture was concentrated under reduced pressure, and the remaining residue was purified by flash column chromatography (petroleum ether and ethyl acetate) to afford the desired product **5** (30%) as a white solid (mp: 92- 94 °C). $R_f = 0.4$ (silica gel, PE:EtOAc = 20:1).

^1H NMR (500 MHz, CDCl_3) δ 8.51 – 8.34 (m, 3H), 7.93 (s, 1H), 7.78 (t, $J = 7.6$ Hz, 1H), 7.58 (t, $J = 7.3$ Hz, 1H), 7.44 (t, $J = 7.5$ Hz, 1H), 7.31 (t, $J = 7.6$ Hz, 1H), 7.24 (d, $J = 8.0$ Hz, 1H), 3.12 (s, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 138.3, 138.0, 135.8, 131.5, 128.0, 126.2, 123.9, 123.4, 122.1, 121.9, 119.0, 95.0. ^{11}B NMR (160 MHz, CDCl_3) δ 25.2 (s). HRMS (EI) calcd for $\text{C}_{14}\text{H}_{10}\text{BN}$: 203.0906, found: 203.0915

3. Synthesis of oxime chlorides




The oxime chloride **2a-2r** were prepared according to the reference.^{3,4}

A 100 mL round-bottomed flask was charged with aldehyde (5 mmol, 1 equiv), hydroxylamine hydrochloride (10 mmol, 2 equiv), 2.5 mL H_2O and 22.5 mL methanol. Then, $\text{CH}_3\text{CO}_2\text{Na}$ (10 mmol, 2 equiv) was added to the solution. The reaction was stirred at room temperature for 2 h. Upon completion, methanol was removed, aqueous layers was extracted with ethyl acetate thrice. The combine organic layers were dried over anhydrous Na_2SO_4 . After removal of the solvent, the crude aldoxime was used in the next step.

A 100 mL round-bottomed flask was charged with the crude aldoxime of the first step and 15 mL DMF. Then, N-chlorosuccinimide (5.5 mmol, 1.1 equiv) in 15 mL DMF was added dropwise over a period of 20 minutes to the solution. The reaction was stirred for 2 hours at room temperature. Upon completion, the reaction mixture was diluted with 5% LiCl (aq), extracted with ethyl acetate thrice, the combine organic layers were washed with 5% LiCl (aq) and brine and dried over anhydrous Na_2SO_4 . After removal of the solvent, the residue purified on silica gel (petroleum ether: ethyl acetate = 30:1-5:1) to afford desired oxime chloride.


N-hydroxy-4-methoxybenzimidoyl chloride (2a)



The general procedure was followed by using 4-methoxybenzaldehyde (4 mmol) to afford the desired product **2a** (85%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.53 (s, 1H), 7.89 – 7.66 (m, 2H), 6.95 – 6.89 (m, 2H), 3.85 (s, 3H).


N-hydroxybenzimidoyl chloride (2b)



The general procedure was followed by using benzaldehyde (4 mmol) to afford the desired product **2b** (71%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.40 (s, 1H), 7.91 – 7.79 (m, 2H), 7.49 – 7.37 (m, 3H).


N-hydroxy-4-phenoxybenzimidoyl chloride (2c)



The general procedure was followed by using 4-phenoxy benzaldehyde (4 mmol) to afford the desired product **2c** (95%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.47 (s, 1H), 7.83 – 7.76 (m, 2H), 7.38 (dd, *J* = 8.6, 7.4 Hz, 2H), 7.21 – 7.15 (m, 1H), 7.10 – 7.04 (m, 2H), 7.03 – 6.99 (m, 2H).


N-hydroxy-4-methylbenzimidoyl chloride (2d)



The general procedure was followed by using 4-methylbenzaldehyde (4 mmol) to afford the desired product **2d** (80%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.34 (s, 1H), 7.73 (d, *J* = 7.9 Hz, 2H), 7.21 (d, *J* = 7.9 Hz, 2H), 2.39.


N-hydroxy-3-methylbenzimidoyl chloride (2e)



The general procedure was followed by using 3-methylbenzaldehyde (4 mmol) to afford the desired product **2e** (85%) as a colorless oil. Known compound.⁴

¹H NMR NMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 7.65 (d, *J* = 8.3 Hz, 2H), 7.34 – 7.24 (m, 2H), 2.40 (s, 3H).


N-hydroxy-3,4-dimethylbenzimidoyl chloride (**2f**)



The general procedure was followed by using 3,4-dimethylbenzaldehyde (4 mmol) to afford the desired product **2f** (80%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.51 (s, 1H), 7.60 (d, *J* = 1.9 Hz, 1H), 7.56 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.17 (d, *J* = 8.0 Hz, 1H), 2.30 (s, 6H).


N-hydroxy-2,4,6-trimethylbenzimidoyl chloride (**2g**)



The general procedure was followed by using 2,4,6-trimethylbenzaldehyde (4 mmol) to afford the desired product **2g** (75%) as a colorless oil. Known compound.⁴

¹H NMR (400 MHz, CDCl₃) δ 6.90 (s, 2H), 2.41 (s, 6H), 2.30 (s, 3H).


N-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzimidoyl chloride (**2h**)



The general procedure was followed by using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (4 mmol) to afford the desired product **2h** (55%) as a colorless oil. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.79 (s, 1H), 7.88 – 7.79 (m, 4H), 1.37 (s, 12H).


N-hydroxy-3-(trifluoromethoxy)benzimidoyl chloride (**2i**)



The general procedure was followed by using 3-(trifluoromethoxy)benzaldehyde (4 mmol) to afford the desired product **2i** (55%) as a colorless oil. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.51 (s, 1H), 7.81 – 7.76 (m, 1H), 7.71 (s, 1H), 7.44 (t, *J* = 8.1 Hz, 1H), 7.33 – 7.27 (m, 1H).


N-hydroxy-3-iodobenzimidoyl chloride (**2j**)



The general procedure was followed by using 3-iodobenzaldehyde (4 mmol) to afford the desired product **2j** (65%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.60 (s, 1H), 8.19 (s, 1H), 7.82 – 7.74 (m, 2H), 7.14 (t, *J* = 7.9 Hz, 1H).


3-bromo-N-hydroxybenzimidoyl chloride (2k)



The general procedure was followed by using 3-bromobenzaldehyde (4 mmol) to afford the desired product **2k** (75%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.33 (s, 1H), 8.00 (t, *J* = 1.9 Hz, 1H), 7.79 – 7.76 (m, 1H), 7.60 – 7.55 (m, 1H), 7.28 (t, *J* = 8.0 Hz, 1H).


3-fluoro-N-hydroxybenzimidoyl chloride (2l)



The general procedure was followed by using 3-fluorobenzaldehyde (4 mmol) to afford the desired product **2l** (73%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.32 (s, 1H), 7.69 – 7.62 (m, 1H), 7.60 – 7.52 (m, 1H), 7.41 – 7.35 (m, 1H), 7.19 – 7.10 (m, 1H).


2-bromo-4-chloro-N-hydroxybenzimidoyl chloride (2m)



The general procedure was followed by using 2-bromo-4-chlorobenzaldehyde (4 mmol) to afford the desired product **2m** (80%) as a white solid (mp: 94-96 °C). R_f = 0.5 (silica gel, PE:EtOAc = 20:1).

¹H NMR NMR (500 MHz, CDCl₃) δ 8.80 (s, 1H), 7.66 (d, *J* = 2.0 Hz, 1H), 7.42 – 7.34 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 137.4, 137.0, 133.2, 132.9, 131.8, 127.8, 122.7. HRMS (ESI) calcd for C₇H₅BrCl₂NO [M+H]⁺: 267.8932, found: 267.8931.


methyl 4-(chloro(hydroxyimino)methyl)benzoate (2n)



The general procedure was followed by using methyl 4-formylbenzoate (4 mmol) to afford the desired product **2n** (81%) as a white solid. Known compound.⁴

¹H NMR NMR (500 MHz, CDCl₃) δ 8.84 (s, 1H), 8.06 (d, *J* = 8.6 Hz), 7.91 (d, *J* = 8.4 Hz), 3.95 (s, 3H).


N-hydroxy-1-naphthimidoyl chloride (2o)



The general procedure was followed by using 1-naphthaldehyde (4 mmol) to afford the desired product **2o** (65%) as a white solid. Known compound.⁴

$^1\text{H NMR NMR (500 MHz, CDCl}_3)$ δ 8.63 (s, 1H), 8.24 (d, $J = 8.2$ Hz, 1H), 7.97 – 7.87 (m, 2H), 7.72 (dd, $J = 7.2, 1.2$ Hz, 1H), 7.61 – 7.48 (m, 3H).


N-hydroxy-2-naphthimidoyl chloride (2p)



The general procedure was followed by using 2-naphthaldehyde (4 mmol) to afford the desired product **2p** (60%) as a white solid. Known compound.⁴

$^1\text{H NMR NMR (500 MHz, CDCl}_3)$ δ 8.65 (s, 1H), 8.34 (s, 1H), 7.96 – 7.81 (m, 4H), 7.60 – 7.48 (m, 2H).


N-hydroxycinnamimidoyl chloride (2q)



The general procedure was followed by using cinnamaldehyde (4 mmol) to afford the desired product **2q** (61%) as a colorless oil. Known compound.⁴


$^1\text{H NMR NMR (500 MHz, CDCl}_3)$ δ 8.67 (s, 1H), 7.52 – 7.47 (m, 2H), 7.41 – 7.30 (m, 4H), 6.88 (d, $J = 15.7$ Hz, 1H).

N-hydroxy-3-(4-methoxyphenyl)acrylimidoyl chloride (2r)



The general procedure was followed by using 3-(4-methoxyphenyl)acrylaldehyde (4 mmol) to afford the desired product **2r** (65%) as a brown solid. Known compound.⁴

$^1\text{H NMR NMR (500 MHz, CDCl}_3)$ δ 8.79 (s, 1H), 7.43 (d, $J = 8.7$ Hz, 2H), 7.26 (d, $J = 15.7$ Hz, 1H), 6.90 (d, $J = 8.8$ Hz, 2H), 6.74 (d, $J = 15.6$ Hz, 1H), 3.83 (s, 3H).




The oxime chloride **2u** were prepared according to the reference.⁵

To a solution of glycine ester hydrochloride (2 g, 14 mmol) in 3 mL water was added conc.HCl (1.2 mL). Upon completion of addition, the resulting solution was cooled to -5 °C and then a solution of sodium nitrite (1 g, 14 mmol) in water (1.4 mL) was added. The resulting mixture was stirred at 0 °C for 10 min and then another a sodium nitrite (1 g, 14 mmol) in water (1.4 mL) was added. The resulting mixture was stirred at 0 °C for 45 min. Upon completion, a brine solution was added. The reaction mixture was extracted with ether thrice, dried over anhydrous Na_2SO_4 , evaporated under reduced pressure to yield oxime chloride **2u**, was taken to the next step immediately without further purification.


4. General procedure for the regioselective [3+2] cycloaddition reaction

A. Synthesis of 5-(2,1-azaborine) substituted isoxazoles



In air, a 25 mL schlenk tube was charged with **1** or **5** (0.2 mmol, 2 equiv) and **2** (0.3 mmol, 1.5 equiv). The tube was evacuated and filled with argon for three cycles. Then, DCE (2 mL) and DIPEA (0.3 mmol, 1.5 equiv) were added under argon. The reaction was allowed to stir at room temperature for 12 hours. Upon completion, proper amount of silica gel was added to the reaction mixture. After removal of the solvent, the crude reaction mixture was purified on silica gel (petroleum ether and ethyl acetate) to afford the desired products **3** or **6**.


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (**3a**)



White solid, mp: 185-186 °C. Yield: 85%. $R_f = 0.3$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$) δ 11.08 (s, 1H), 8.28 (d, $J = 11.4$ Hz, 1H), 7.89 (d, $J = 8.3$ Hz, 2H), 7.78 (dd, $J = 14.0, 8.0$ Hz, 2H), 7.67 (s, 1H), 7.54 (t, $J = 7.7$ Hz, 1H), 7.29 – 7.21 (m, 2H), 7.10 (d, $J = 8.3$ Hz, 2H), 3.83 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, $\text{DMSO-}d_6$) δ 160.8, 160.6, 146.6, 140.2, 129.4, 128.9, 128.18, 125.5, 121.5, 121.2, 119.0, 114.6, 110.8, 55.3. $^{11}\text{B NMR}$ (160 MHz, $\text{DMSO-}d_6$) δ 27.1 (s). **HRMS (EI)** calcd for $\text{C}_{18}\text{H}_{15}\text{BN}_2\text{O}_2$: 302.1227, found: 302.1232


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenylisoxazole (**3b**)



White solid, mp: 166-168 °C. Yield: 87%. $R_f = 0.6$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$) δ 11.11 (s, 1H), 8.29 (d, $J = 11.5$ Hz, 1H), 8.00 – 7.92 (m, 2H), 7.82 – 7.76 (m, 2H), 7.74 (s, 1H), 7.60 – 7.48 (m, 4H), 7.30 – 7.22 (m, 2H). $^{13}\text{C NMR}$ (126 MHz, $\text{DMSO-}d_6$) δ 161.2, 146.6, 140.2, 130.0, 129.4, 129.2, 129.2, 128.9, 126.7, 125.5, 121.6, 119.21, found: 272.11120, 111.0. $^{11}\text{B NMR}$ (160 MHz, $\text{DMSO-}d_6$) δ 27.3(s). **HRMS (EI)** calcd for $\text{C}_{17}\text{H}_{13}\text{BN}_2\text{O}$: 272.11


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-phenoxyphenyl)isoxazole (**3c**)



White solid, mp: 100-102 °C. Yield: 90%. $R_f = 0.3$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$) δ 11.10 (s, 1H), 8.28 (d, $J = 11.5$ Hz, 1H), 7.96 (d, $J = 8.4$ Hz, 2H), 7.78 (dd, $J = 11.5, 8.1$ Hz, 2H), 7.70 (s, 1H), 7.54 (t, $J = 7.6$ Hz, 1H), 7.44 (t, $J = 7.8$ Hz, 2H), 7.30 – 7.18 (m, 3H), 7.13 (dd, $J = 13.4, 8.2$ Hz, 4H). $^{13}\text{C NMR}$ (126 MHz, $\text{DMSO-}d_6$) δ 160.6, 158.4, 155.83, 146.6, 140.2, 130.2, 129.4, 128.9, 128.6, 125.5, 124.2, 123.7, 121.5, 119.4, 119.0, 118.6, 110.9. $^{11}\text{B NMR}$ (160 MHz, $\text{DMSO-}d_6$) δ 28.3 (s). **HRMS (EI)** calcd for $\text{C}_{23}\text{H}_{17}\text{BN}_2\text{O}_2$: 364.1383, found: 364.1385


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3d)



White solid, mp: 169-171 °C. Yield: 91%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, DMSO- d_6) δ 11.09 (s, 1H), 8.28 (d, $J = 11.4$ Hz, 1H), 7.84 (d, $J = 7.8$ Hz, 2H), 7.78 (dd, $J = 13.0, 8.0$ Hz, 2H), 7.70 (s, 1H), 7.54 (t, $J = 7.7$ Hz, 1H), 7.35 (d, $J = 7.7$ Hz, 2H), 7.30 – 7.21 (m, 2H), 2.37 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, DMSO- d_6) δ 161.1, 146.6, 140.2, 139.6, 129.7, 129.4, 128.9, 126.6, 126.0, 125.5, 121.5, 119.0, 110.9, 20.9. $^{11}\text{B NMR}$ (160 MHz, DMSO- d_6) δ 27.3 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{15}\text{BN}_2\text{O}$: 286.1277, found: 286.1276


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3e)



White solid, mp: 233-234 °C. Yield: 92%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, DMSO- d_6) δ 11.09 (s, 1H), 8.29 (d, $J = 11.4$ Hz, 1H), 7.82 – 7.71 (m, 5H), 7.60 – 7.49 (m, 1H), 7.43 (t, $J = 7.6$ Hz, 1H), 7.32 (d, $J = 7.6$ Hz, 1H), 7.29 – 7.21 (m, 2H), 2.40 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, DMSO- d_6) δ 161.2, 146.6, 140.2, 138.5, 130.6, 129.4, 129.1, 128.9, 128.7, 127.21, 125.5, 123.9, 121.5, 119.0, 111.1, 20.9. $^{11}\text{B NMR}$ (160 MHz, DMSO- d_6) δ 26.9. HRMS (EI) calcd for $\text{C}_{18}\text{H}_{15}\text{BN}_2\text{O}$: 286.1277, found: 286.1273


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3,4-dimethylphenyl)isoxazole (3f)



White solid, mp: 157-159 °C. Yield: 91%. $R_f = 0.6$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, DMSO- d_6) δ 11.08 (s, 1H), 8.28 (d, $J = 11.4$ Hz, 1H), 7.81 – 7.74 (m, 2H), 7.73 (d, $J = 1.7$ Hz, 1H), 7.69 (s, 1H), 7.65 (dd, $J = 7.5, 1.8$ Hz, 1H), 7.57 – 7.50 (m, 1H), 7.29 (d, $J = 7.9$ Hz, 1H), 7.27 – 7.22 (m, 2H), 2.31 (s, 3H), 2.27 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, DMSO- d_6) δ 161.1, 146.6, 140.2, 138.4, 137.1, 130.2, 129.4, 128.9, 127.6, 126.3, 125.5, 124.2, 121.5, 119.0, 111.0, 19.4, 19.3. $^{11}\text{B NMR}$ (160 MHz, DMSO- d_6) δ 27.0 (s). HRMS (EI) calcd for $\text{C}_{19}\text{H}_{17}\text{BN}_2\text{O}$: 300.1434, found: 300.1431


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-mesitylisoxazole (3g)



White solid, mp: 210-212 °C. Yield: 48%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, DMSO- d_6) δ 11.02 (s, 1H), 8.24 (d, $J = 11.4$ Hz, 1H), 7.86 – 7.62 (m, 2H), 7.60 – 7.40 (m, 1H), 7.26 – 7.16 (m, 3H), 6.96 (s, 2H), 2.25 (s, 3H), 2.06 (s, 6H). $^{13}\text{C NMR}$ (126 MHz, DMSO- d_6) δ 160.6, 146.6, 140.2, 138.1, 136.5, 129.4, 129.0, 128.3, 126.3, 125.5, 121.6, 119.0, 114.2, 20.7, 20.0. $^{11}\text{B NMR}$ (160 MHz, DMSO- d_6) δ 27.5 (s). HRMS (EI) calcd for $\text{C}_{20}\text{H}_{19}\text{BN}_2\text{O}$: 314.1590, found: 314.1586


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole (3h)



White solid, mp: 200-201 °C. Yield: 93%. $R_f = 0.2$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, DMSO- d_6) δ 11.11 (s, 1H), 8.29 (d, $J = 11.4$ Hz, 1H), 7.98 (d, $J = 7.9$ Hz, 2H), 7.85 (d, $J = 7.8$ Hz, 2H), 7.82 – 7.73 (m, 3H), 7.64 – 7.44 (m, 1H), 7.38 – 7.09 (m, 2H), 1.31 (s, 12H). **^{13}C NMR (126 MHz, DMSO- d_6)** δ 161.0, 146.7, 140.2, 135.2, 131.5, 129.4, 129.0, 126.1, 125.5, 121.6, 119.0, 111.1, 83.9, 24.7. **^{11}B NMR (160 MHz, DMSO- d_6)** δ 27.3 (s). **HRMS (ESI)** calcd for $\text{C}_{23}\text{H}_{25}\text{B}_2\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: 399.2051, found: 399.2042


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-(trifluoromethoxy)phenyl)isoxazole (3i)



White solid, mp: 109-110 °C. Yield: 92%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, DMSO- d_6) δ 11.13 (s, 1H), 8.29 (d, $J = 11.4$ Hz, 1H), 8.00 (d, $J = 7.8$ Hz, 1H), 7.91 (s, 1H), 7.84 (s, 1H), 7.78 (dd, $J = 11.0, 8.0$ Hz, 2H), 7.70 (t, $J = 8.0$ Hz, 1H), 7.53 (d, $J = 8.1$ Hz, 2H), 7.33 – 7.18 (m, 2H). **^{13}C NMR (126 MHz, DMSO- d_6)** δ 160.09, 148.91, 146.69, 140.16, 131.42, 131.07, 129.38, 128.97, 125.85, 125.55, 122.50, 121.59, 120.1 (q, $J = 257.04$ Hz), 119.13, 119.03, 111.23. **^{11}B NMR (160 MHz, DMSO- d_6)** δ 26.2 (s). **^{19}F NMR (471 MHz, DMSO- d_6)** δ -56.69 (s). **HRMS (EI)** calcd for $\text{C}_{18}\text{H}_{12}\text{BF}_3\text{N}_2\text{O}_2$: 356.0944, found: 356.0942


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-iodophenyl)isoxazole (3j)



White solid, mp: 163-164 °C. Yield: 93%. $R_f = 0.3$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, DMSO- d_6) δ 11.10 (s, 1H), 8.33 – 8.24 (m, 2H), 7.97 (d, $J = 7.6$ Hz, 1H), 7.87 (d, $J = 7.8$ Hz, 1H), 7.81 – 7.72 (m, 3H), 7.53 (t, $J = 7.6$ Hz, 1H), 7.35 (t, $J = 7.8$ Hz, 1H), 7.28 – 7.20 (m, 2H). **^{13}C NMR (126 MHz, DMSO- d_6)** δ 160.0, 146.7, 140.2, 138.6, 135.0, 131.3, 131.0, 129.4, 129.0, 126.1, 125.6, 121.7, 119.1, 111.2, 95.5. **^{11}B NMR (160 MHz, DMSO- d_6)** δ 27.2 (s). **HRMS (EI)** calcd for $\text{C}_{17}\text{H}_{12}\text{BIN}_2\text{O}$: 398.0087, found: 398.0078

5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-bromophenyl)isoxazole (3k)




White solid, mp: 163-165 °C. Yield: 86%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, DMSO- d_6) δ 11.11 (s, 1H), 8.29 (d, $J = 11.5$ Hz, 1H), 8.13 (t, $J = 1.9$ Hz, 1H), 7.97 (d, $J = 7.7$ Hz, 1H), 7.82 (s, 1H), 7.81 – 7.74 (m, 2H), 7.72 (dd, $J = 8.0, 1.9$ Hz, 1H), 7.58 – 7.46 (m, 2H), 7.29 – 7.20 (m, 2H). **^{13}C NMR (126 MHz, DMSO- d_6)** δ 160.0, 146.7, 140.2, 132.8, 131.4, 131.1, 129.4, 129.2, 129.0, 125.7, 125.5, 122.4, 121.6, 119.0, 111.2. **^{11}B NMR (160 MHz, DMSO- d_6)** δ 27.2 (s). **HRMS (EI)**

calcd for C₁₇H₁₂BBrN₂O: 350.0226, found: 350.0220


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole(3l)



White solid, mp: 167-168 °C. Yield: 94%. R_f = 0.5 (silica gel, PE:EtOAc = 10:1)

¹H NMR NMR (500 MHz, DMSO-*d*₆) δ 11.12 (s, 1H), 8.29 (d, *J* = 11.4 Hz, 1H), 7.85 – 7.74 (m, 5H), 7.65 – 7.57 (m, 1H), 7.57 – 7.51 (m, 1H), 7.41 – 7.33 (m, 1H), 7.30 – 7.20 (m, 2H). **¹³C NMR (126 MHz, DMSO-*d*₆)** δ 162.5 (d, *J* = 243.2 Hz), 160.3 (d, *J* = 2.9 Hz), 146.7, 140.2, 131.4 (d, *J* = 8.4 Hz), 131.1 (d, *J* = 8.4 Hz), 129.4, 128.9, 125.5, 122.9 (d, *J* = 2.9 Hz), 121.6, 119.0, 116.8 (d, *J* = 21.1 Hz), 113.5 (d, *J* = 23.0 Hz), 111.2. **¹¹B NMR (160 MHz, DMSO-*d*₆)** δ 27.6 (s). **¹⁹F NMR (471 MHz, DMSO-*d*₆)** δ -111.99 (s). **HRMS (EI)** calcd for C₁₇H₁₂BFN₂O: 290.1027, found: 290.1021


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(2-bromo-4-chlorophenyl)isoxazole (3m)



White solid, mp: 181-182 °C. Yield: 85%. R_f = 0.4 (silica gel, PE:EtOAc = 10:1)

¹H NMR NMR (500 MHz, DMSO-*d*₆) δ 11.14 (s, 1H), 8.29 (d, *J* = 11.5 Hz, 1H), 7.99 (d, *J* = 2.1 Hz, 1H), 7.77 (dd, *J* = 8.2, 2.2 Hz, 2H), 7.71 (d, *J* = 8.2 Hz, 1H), 7.66 – 7.61 (m, 2H), 7.59 – 7.50 (m, 1H), 7.32 – 7.19 (m, 2H). **¹³C NMR (126 MHz, DMSO-*d*₆)** δ 160.5, 146.7, 140.2, 132.8, 132.6, 129.4, 129.4, 129.0, 128.3, 125.5, 122.4, 121.6, 119.0, 113.6, 113.6. **¹¹B NMR (160 MHz, DMSO-*d*₆)** δ 27.3 (s). **HRMS (EI)** calcd for C₁₇H₁₁BBrClN₂O: 383.9836, found: 383.9834


methyl 3-(5-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazol-3-yl)benzoate (3n)



White solid, mp: 225-226 °C. Yield: 80%. R_f = 0.3 (silica gel, PE:EtOAc = 10:1)

¹H NMR NMR (500 MHz, DMSO-*d*₆) δ 11.12 (s, 1H), 8.29 (d, *J* = 11.5 Hz, 1H), 8.10 (q, *J* = 8.1 Hz, 4H), 7.78 (dd, *J* = 18.0, 8.9 Hz, 3H), 7.54 (t, *J* = 7.7 Hz, 1H), 7.25 (t, *J* = 8.2 Hz, 2H), 3.88 (s, 3H). **¹³C NMR (126 MHz, DMSO-*d*₆)** δ 165.7, 160.4, 146.7, 140.2, 133.1, 130.7, 130.0, 129.4, 129.0, 127.0, 125.6, 121.6, 119.0, 111.2, 52.3. **¹¹B NMR (160 MHz, DMSO-*d*₆)** δ 26.3 (s). **HRMS (EI)** calcd for C₁₉H₁₅BN₂O₃: 330.1176 found: 330.1175

5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphth654-alen-1-yl)isoxazole (3o)




White solid, mp: 141-143 °C. Yield: 88%. R_f = 0.5 (silica gel, PE:EtOAc = 10:1)

¹H NMR NMR (500 MHz, DMSO-*d*₆) δ 11.16 (s, 1H), 8.46 (d, *J* = 8.0 Hz, 1H), 8.31 (d, *J* = 11.5 Hz, 1H),

8.17 – 8.00 (m, 2H), 7.88 (d, $J = 6.9$ Hz, 1H), 7.79 (t, $J = 7.7$ Hz, 2H), 7.74 – 7.60 (m, 4H), 7.56 (t, $J = 7.6$ Hz, 1H), 7.36 – 7.22 (m, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 161.3, 146.7, 140.2, 133.5, 130.36, 130.1, 129.4, 129.0, 128.6, 128.0, 127.3, 126.6, 126.4, 125.6, 125.6, 125.4, 121.6, 119.0, 114.1. ^{11}B NMR (160 MHz, DMSO- d_6) δ 27.3 (s). HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{16}\text{BN}_2\text{O}$ [$\text{M}+\text{H}$] $^+$: 323.1356, found: 323.1357


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphthalen-2-yl)isoxazole (3p)



White solid, mp: 204-206 °C. Yield: 84%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, DMSO- d_6) δ 11.15 (s, 1H), 8.54 (s, 1H), 8.31 (d, $J = 11.4$ Hz, 1H), 8.08 (dd, $J = 8.6, 3.8$ Hz, 3H), 8.04 – 7.96 (m, 1H), 7.90 (s, 1H), 7.80 (dd, $J = 19.3, 8.0$ Hz, 2H), 7.65 – 7.53 (m, 3H), 7.36 – 7.21 (m, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 161.2, 146.6, 140.2, 133.5, 132.9, 129.4, 129.0, 128.8, 128.4, 127.8, 127.1, 126.9, 126.4, 126.3, 125.5, 124.0, 121.5, 119.0, 111.3. ^{11}B NMR (160 MHz, DMSO- d_6) δ 27.2 (s). HRMS (EI) calcd for $\text{C}_{21}\text{H}_{15}\text{BN}_2\text{O}$: 322.1277, found: 322.1275


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-styrylisoxazole (3q)



White solid, mp: 184-186 °C. Yield: 90%. $R_f = 0.2$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, DMSO- d_6) δ 11.08 (s, 1H), 8.28 (d, $J = 11.5$ Hz, 1H), 7.83 – 7.74 (m, 2H), 7.74 – 7.67 (m, 2H), 7.64 (s, 1H), 7.57 – 7.32 (m, 6H), 7.29 – 7.19 (m, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 160.8, 146.6, 140.2, 135.8, 135.8, 129.3, 128.9, 128.9, 128.9, 127.1, 125.5, 121.5, 119.0, 115.9, 110.3. ^{11}B NMR (160 MHz, DMSO- d_6) δ 27.4 (s). HRMS (EI) calcd for $\text{C}_{19}\text{H}_{15}\text{BN}_2\text{O}$: 298.1277, found: 298.1278


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxystyryl)isoxazole (3r)



White solid, mp: 189-190 °C. Yield: 93%. $R_f = 0.1$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, DMSO- d_6) δ 11.06 (s, 1H), 8.28 (d, $J = 11.5$ Hz, 1H), 7.82 – 7.73 (m, 2H), 7.68 – 7.62 (m, 2H), 7.60 (s, 1H), 7.56 – 7.50 (m, 1H), 7.41 (d, $J = 16.5$ Hz, 1H), 7.29 – 7.17 (m, 3H), 7.02 – 6.95 (m, 2H), 3.79 (s, 3H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 171.0, 159.9, 146.6, 140.2, 135.5, 129.3, 128.9, 128.6, 128.4, 125.5, 121.5, 119.0, 114.3, 113.4, 110.2, 55.2. ^{11}B NMR (160 MHz, DMSO- d_6) δ 26.9 (s). HRMS (EI) calcd for $\text{C}_{20}\text{H}_{17}\text{BN}_2\text{O}_2$: 328.1383, found: 328.1382

5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenethylisoxazole (3s)




White solid, mp: 159-161 °C. Yield: 75%. $R_f = 0.6$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.62 (s, 1H), 8.20 (d, $J = 11.5$ Hz, 1H), 7.69 (d, $J = 7.9$ Hz, 1H), 7.50 (t, $J = 7.7$ Hz, 1H), 7.40 (d, $J = 8.3$ Hz, 1H), 7.37 – 7.20 (m, 6H), 7.13 (d, $J = 11.4$ Hz, 1H), 6.72 (s, 1H), 3.32 –

2.86 (m, $J = 4.3$ Hz, 4H). ^{13}C NMR (126 MHz, CDCl_3) δ 162.5, 146.8, 140.7, 139.4, 129.6, 129.0, 128.5, 128.4, 126.3, 125.9, 121.8, 118.6, 112.6, 34.7, 27.6. ^{11}B NMR (160 MHz, CDCl_3) δ 27.0 (s). HRMS (EI) calcd for $\text{C}_{19}\text{H}_{17}\text{BN}_2\text{O}$: 300.1434, found: 300.1426


5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-bromoisoxazole (3t)



White solid, mp: 186-188 °C. Yield: 26%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.12 (s, 1H), 8.29 (d, $J = 11.4$ Hz, 1H), 7.82 – 7.70 (m, 2H), 7.58 – 7.52 (m, 1H), 7.48 (s, 1H), 7.31 – 7.24 (m, 1H), 7.19 (dd, $J = 11.4, 1.8$ Hz, 1H). ^{13}C NMR (126 MHz, $\text{DMSO}-d_6$) δ 146.9, 140.0, 139.8, 129.4, 129.1, 125.6, 121.8, 119.0, 115.8. ^{11}B NMR (160 MHz, $\text{DMSO}-d_6$) δ 26.82 (s). HRMS (EI) calcd for $\text{C}_{11}\text{H}_8\text{BBrN}_2\text{O}$: 273.9913, found: 273.9908


ethyl 5-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole-3-carboxylate (3u)



White solid, mp: 114-115 °C. Yield: 28%. $R_f = 0.2$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.67 (s, 1H), 8.24 (d, $J = 11.6$ Hz, 1H), 7.71 (d, $J = 8.2$ Hz, 1H), 7.52 (t, $J = 7.6$ Hz, 1H), 7.44 (d, $J = 8.2$ Hz, 1H), 7.34 – 7.23 (m, 2H), 7.17 (d, $J = 11.7$ Hz, 1H), 4.49 (q, $J = 7.1$ Hz, 2H), 1.45 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 171.8, 160.3, 156.0, 147.3, 139.2, 129.7, 129.2, 126.0, 122.2, 118.7, 113.0, 62.2, 14.2. ^{11}B NMR (160 MHz, CDCl_3) δ 24.6 (s). HRMS (EI) calcd for $\text{C}_{14}\text{H}_{13}\text{BN}_2\text{O}_3$: 268.1019, found: 268.1014


5-(6-methoxybenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3v)



White solid, mp: 204-205 °C. Yield: 86%. $R_f = 0.2$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.99 (s, 1H), 8.24 (d, $J = 11.4$ Hz, 1H), 7.88 (d, $J = 8.3$ Hz, 2H), 7.71 (d, $J = 8.9$ Hz, 1H), 7.6 (s, 1H), 7.28 (d, $J = 3.0$ Hz, 1H), 7.26 – 7.16 (m, 2H), 7.09 (d, $J = 8.4$ Hz, 2H), 3.83 (s, 6H). ^{13}C NMR (126 MHz, $\text{DMSO}-d_6$) δ 160.7, 160.5, 153.9, 146.0, 134.9, 128.2, 126.1, 121.3, 120.1, 118.6, 114.6, 110.4, 110.1, 55.3, 55.3. ^{11}B NMR (160 MHz, $\text{DMSO}-d_6$) δ 24.4 (s). HRMS (EI) calcd for $\text{C}_{19}\text{H}_{17}\text{BN}_2\text{O}_3$: 332.1332, found: 332.1328

5-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3w)




White solid, mp: 215-216 °C. Yield: 91%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.15 (s, 1H), 8.26 (d, $J = 11.5$ Hz, 1H), 7.93 – 7.85 (m, 2H), 7.81 (dd, $J = 9.1, 5.1$ Hz, 1H), 7.66 (s, 1H), 7.61 (dd, $J = 9.6, 3.0$ Hz, 1H), 7.50 – 7.38 (m, 1H), 7.30 (dd, $J = 11.5, 1.7$ Hz, 1H), 7.17 – 7.01 (m, 2H), 3.82 (s, 3H). ^{13}C NMR (126 MHz, $\text{DMSO}-d_6$) δ 160.7 (d, $J = 26.7$ Hz),

157.8, 155.9, 145.8, 136.9, 128.2, 126.01 (d, $J = 8.6$ Hz), 121.2, 120.7 (d, $J = 8.4$ Hz), 117.2 (d, $J = 24.2$ Hz), 114.6, 113.5 (d, $J = 21.5$ Hz), 111.0. ^{11}B NMR (160 MHz, $\text{DMSO-}d_6$) δ 27.4 (s). ^{19}F NMR (471 MHz, $\text{DMSO-}d_6$) δ -121.41 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{14}\text{BFN}_2\text{O}_2$: 320.1132, found: 320.1129


5-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3x)



White solid, mp: 213-214 °C. Yield: 83%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, $\text{DMSO-}d_6$) δ 11.16 (s, 1H), 8.28 (d, $J = 11.5$ Hz, 1H), 7.91 – 7.85 (m, 2H), 7.83 (dd, $J = 8.8, 6.4$ Hz, 1H), 7.67 (s, 1H), 7.55 (dd, $J = 10.7, 2.6$ Hz, 1H), 7.19 (dd, $J = 11.4, 1.7$ Hz, 1H), 7.16 – 7.07 (m, 3H), 3.82 (s, 3H). ^{13}C NMR (126 MHz, $\text{DMSO-}d_6$) δ 163.1, 161.1, 160.7 (d, $J = 30.9$ Hz), 146.2, 141.4 (d, $J = 12.0$ Hz), 131.6 (d, $J = 10.2$ Hz), 128.2, 122.6, 121.1, 114.6, 111.2, 110.0 (d, $J = 23.2$ Hz), 104.4 (d, $J = 24.1$ Hz), 55.3. ^{11}B NMR (160 MHz, $\text{DMSO-}d_6$) δ 25.6 (s). ^{19}F NMR (471 MHz, $\text{DMSO-}d_6$) δ -110.98 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{14}\text{BFN}_2\text{O}_2$: 320.1132, found: 320.1140


3-(4-methoxyphenyl)-5-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (3y)



White solid, mp: 186-187 °C. Yield: 85%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, $\text{DMSO-}d_6$) δ 11.27 (s, 1H), 8.33 (d, $J = 11.4$ Hz, 1H), 7.88 (d, $J = 8.5$ Hz, 3H), 7.83 (d, $J = 2.7$ Hz, 1H), 7.69 (s, 1H), 7.55 (dd, $J = 8.8, 2.7$ Hz, 1H), 7.33 (dd, $J = 11.3, 1.6$ Hz, 1H), 7.09 (d, $J = 8.4$ Hz, 2H), 3.82 (s, 3H). ^{13}C NMR (126 MHz, $\text{DMSO-}d_6$) δ 160.8, 160.6, 146.0, 142.3, 139.0, 128.2, 125.8, 122.3, 121.1, 120.3 (q, $J = 256.4$ Hz), 120.9, 120.7, 114.6, 111.3, 55.3. ^{11}B NMR (160 MHz, $\text{DMSO-}d_6$) δ 27.4 (s). ^{19}F NMR (471 MHz, $\text{DMSO-}d_6$) δ -57.58 (s). HRMS (EI) calcd for $\text{C}_{19}\text{H}_{14}\text{BF}_3\text{N}_2\text{O}_3$: 386.1050, found: 386.1058


5-(6-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3z)



White solid, mp: 208-210 °C. Yield: 95%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, $\text{DMSO-}d_6$) δ 11.00(s, 1H), 8.20 (d, $J = 11.4$ Hz, 1H), 7.83 (d, $J = 7.7$ Hz, 2H), 7.67 (d, $J = 10.7$ Hz, 2H), 7.53(s, 1H), 7.35 (t, $J = 6.6$ Hz, 3H), 7.21 (d, $J = 11.4$ Hz, 1H), 2.39(s, 3H), 2.37(s, 3H). ^{13}C NMR (126 MHz, $\text{DMSO-}d_6$) δ 161.0, 146.3, 139.7, 138.3, 130.4, 130.3, 129.7, 128.8, 126.6, 126.1, 125.5, 118.9, 110.7, 21.0, 20.5. ^{11}B NMR (160 MHz, $\text{DMSO-}d_6$) δ 25.5 (s). HRMS (EI) calcd for $\text{C}_{19}\text{H}_{17}\text{BN}_2\text{O}$: 300.1434, found: 300.1439.


5-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3aa)



White solid, mp: 197-199 °C. Yield: 94%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, DMSO- d_6) δ 10.67 (s, 1H), 8.26 (d, $J = 11.5$ Hz, 1H), 7.91 (s, 1H), 7.82 – 7.71 (m, 3H), 7.63 (d, $J = 10.7$ Hz, 1H), 7.36 (dd, $J = 22.9, 9.6$ Hz, 3H), 2.36 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, DMSO- d_6) δ 161.0, 152.6, 150.7, 145.1, 139.6, 129.7, 129.6, 127.9, 127.4 (d, $J = 13.6$ Hz), 126.5, 126.0, 124.5 (d, $J = 9.4$ Hz), 124.3, 114.6 (d, $J = 22.5$ Hz), 111.5, 21.0. $^{11}\text{B NMR}$ (160 MHz, DMSO- d_6) δ 26.2 (s). $^{19}\text{F NMR}$ (471 MHz, DMSO- d_6) δ -129.14 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{13}\text{BClFN}_2\text{O}$: 338.0793, found: 338.0801


5-(4-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3ab)



White solid, mp: 156-158 °C. Yield: 90%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, DMSO- d_6) δ 10.87 (s, 1H), 7.88 (dd, $J = 8.1, 1.4$ Hz, 1H), 7.83 (d, $J = 7.9$ Hz, 2H), 7.81 – 7.76 (m, 1H), 7.66 (s, 1H), 7.57 – 7.50 (m, 1H), 7.34 (d, $J = 7.9$ Hz, 2H), 7.30 – 7.24 (m, 1H), 7.07 (s, 1H), 2.63 (s, 3H), 2.37 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, DMSO- d_6) δ 161.0, 152.9, 140.5, 139.6, 129.7, 128.6, 126.6, 126.1, 125.6, 125.3, 121.4, 119.5, 110.7, 22.8, 21.0. $^{11}\text{B NMR}$ (160 MHz, DMSO- d_6) δ 25.1 (s). HRMS (EI) calcd for $\text{C}_{19}\text{H}_{17}\text{BN}_2\text{O}$: 300.1434, found: 300.1430


5-(4-phenylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3ac)



White solid, mp: 224-225 °C. Yield: 92%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, DMSO- d_6) δ 11.15 (s, 1H), 7.89 (d, $J = 8.1$ Hz, 1H), 7.83 (d, $J = 8.0$ Hz, 1H), 7.75 (s, 1H), 7.59 – 7.51 (m, 4H), 7.51 – 7.43 (m, 3H), 7.34 (d, $J = 8.0$ Hz, 2H), 7.22 – 7.16 (m, 1H), 7.12 (d, $J = 1.9$ Hz, 1H), 2.36 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, DMSO- d_6) δ 161.1, 157.3, 141.8, 141.0, 139.6, 129.7, 128.9, 128.7, 128.4, 127.8, 127.4, 126.6, 126.0, 124.2, 121.5, 119.7, 111.2, 20.9. $^{11}\text{B NMR}$ (160 MHz, DMSO- d_6) δ 25.3 (s). HRMS (EI) calcd for $\text{C}_{24}\text{H}_{19}\text{BN}_2\text{O}$: 362.1590, found: 362.1591

5-(5-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3ad)




White solid, mp: 130-131 °C. Yield: 89%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, DMSO- d_6) δ 11.05 (s, 1H), 8.48 (d, $J = 11.7$ Hz, 1H), 7.78 (s, 1H), 7.76 – 7.71 (m, 2H), 7.66 (d, $J = 8.2$ Hz, 1H), 7.42 (dt, $J = 10.0, 7.6$ Hz, 2H), 7.36 – 7.25 (m, 2H), 7.10 (d, $J = 7.2$ Hz, 1H), 2.60 (s, 3H), 2.41 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, DMSO- d_6) δ 161.2, 142.7, 140.4, 138.5, 135.7, 130.6, 129.1,

128.8, 128.5, 127.2, 127.2, 123.9, 122.9, 117.5, 111.0, 21.0, 19.1. ¹¹B NMR (160 MHz, DMSO-*d*₆) δ 27.1 (s). HRMS (EI) calcd for C₁₉H₁₇BN₂O: 300.1434, found: 300.1432


5-(1-benzylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3ae)



White solid, mp: 138-140 °C. Yield: 88%. R_f = 0.4 (silica gel, PE:EtOAc = 10:1)

¹H NMR (500 MHz, DMSO-*d*₆) δ 8.33 (d, *J* = 11.5 Hz, 1H), 7.85 (d, *J* = 7.8 Hz, 1H), 7.74 (s, 1H), 7.72 – 7.66 (m, 2H), 7.60 (d, *J* = 8.7 Hz, 1H), 7.49 (t, *J* = 7.8 Hz, 1H), 7.39 (t, *J* = 8.3 Hz, 2H), 7.30 (t, *J* = 7.3 Hz, 4H), 7.25 – 7.16 (m, 3H), 5.79 (s, 2H), 2.37 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 161.1, 146.8, 140.5, 138.4, 138.3, 130.7, 130.5, 129.4, 129.0, 128.7, 128.4, 127.3, 127.2, 127.0, 125.8, 123.9, 122.0, 116.9, 113.0, 51.9, 21.0. ¹¹B NMR (160 MHz, DMSO-*d*₆) δ 30.3 (s). HRMS (EI) calcd for C₂₅H₂₁BN₂O: 376.1747, found: 376.1744


5-(1-isopropylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3af)



White solid, mp: 96-98 °C. Yield: 55%. R_f = 0.5 (silica gel, PE:EtOAc = 10:1)

¹H NMR (500 MHz, DMSO-*d*₆) δ 8.18 (d, *J* = 11.3 Hz, 1H), 8.03 (d, *J* = 8.8 Hz, 1H), 7.91 – 7.86 (m, 2H), 7.83 (dd, *J* = 8.0, 1.7 Hz, 1H), 7.65 – 7.57 (m, 1H), 7.55 (s, 1H), 7.32 (dd, *J* = 16.4, 7.8 Hz, 3H), 7.11 (d, *J* = 11.2 Hz, 1H), 5.25 (m, 1H), 2.37 (s, 3H), 1.68 (d, *J* = 6.9 Hz, 6H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 160.9, 146.3, 139.6, 131.0, 129.6, 128.2, 127.9, 126.8, 125.9, 121.5, 118.6, 114.1, 111.2, 52.1, 21.9, 21.0, 20.94. ¹¹B NMR (160 MHz, DMSO-*d*₆) δ 29.3 (s). HRMS (EI) calcd for C₂₁H₂₁BN₂O: 328.1747, found: 328.1741


5-(dibenzo[*c,e*][1,2]azaborinin-6(5H)-yl)-3-(p-tolyl)isoxazole (6)



White solid, mp: 164-165 °C. Yield: 50%. R_f = 0.4 (silica gel, PE:EtOAc = 10:1)


¹H NMR (500 MHz, DMSO-*d*₆) δ 10.71 (s, 1H), 8.68 (t, *J* = 7.4 Hz, 2H), 8.59 (d, *J* = 8.2 Hz, 1H), 7.95 – 7.84 (m, 4H), 7.82 (d, *J* = 8.0 Hz, 1H), 7.65 (t, *J* = 7.4 Hz, 1H), 7.54 (t, *J* = 7.5 Hz, 1H), 7.43 – 7.30 (m, 3H), 2.39 (s, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 161.0, 139.8, 139.0, 138.7, 135.0, 131.8, 129.8, 128.4, 126.8, 126.5, 126.0, 124.0, 123.0, 122.7, 122.3, 119.9, 111.6, 21.00. ¹¹B NMR (160 MHz, DMSO-*d*₆) δ 29.5 (s). HRMS (EI) calcd for C₂₂H₁₇BN₂O: 336.1434, found: 336.1445

B. Synthesis of 4-(2,1-azaborine) substituted isoxazoles



In air, a 25 mL schlenk tube was charged with **1** (0.2 mmol, 2 equiv), **2** (0.24 mmol, 1.2 equiv), AgOTf (5 mol%), [Cp*RuCl(cod)] (5 mol%). The tube was evacuated and filled with argon for three cycles. Then, DCM (2 mL) and DIPEA (0.24 mmol, 1.2 equiv) were added under argon. The reaction was allowed to stir at room temperature for 12 hours. Upon completion, proper amount of silica gel was added to the reaction mixture. After removal of the solvent, the crude reaction mixture was purified on silica gel (petroleum ether and ethyl acetate) to afford the desired products.


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (**4a**)



White solid, mp: 120-122 °C. Yield: 72%. $R_f = 0.3$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR (500 MHz, DMSO-}d_6)$ δ 10.52 (s, 1H), 9.07 (s, 1H), 8.02 (d, $J = 11.5$ Hz, 1H), 7.67 (d, $J = 7.7$ Hz, 1H), 7.55 (d, $J = 8.1$ Hz, 3H), 7.47 (t, $J = 7.7$ Hz, 1H), 7.18 (t, $J = 7.4$ Hz, 1H), 7.02 (d, $J = 8.3$ Hz, 2H), 6.56 (d, $J = 11.4$ Hz, 1H), 3.79 (s, 3H). $^{13}\text{C NMR (126 MHz, DMSO-}d_6)$ δ 164.0, 163.6, 160.3, 144.9, 140.6, 129.8, 129.2, 128.5, 124.9, 122.2, 121.0, 118.5, 114.1, 55.2. $^{11}\text{B NMR (160 MHz, DMSO-}d_6)$ δ 30.8 (s). **HRMS (EI)** calcd for $\text{C}_{18}\text{H}_{15}\text{BN}_2\text{O}_2$: 302.1227, found: 302.1227


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenylisoxazole (**4b**)



White solid, mp: 104-106 °C. Yield: 81%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR (500 MHz, CDCl}_3)$ δ 8.75 (s, 1H), 8.07 (d, $J = 11.6$ Hz, 1H), 7.78 (s, 1H), 7.71 (d, $J = 7.2$ Hz, 2H), 7.63 (d, $J = 7.8$ Hz, 1H), 7.53 (dd, $J = 11.7, 6.9$ Hz, 3H), 7.38 (t, $J = 7.7$ Hz, 1H), 7.19 (t, $J = 7.5$ Hz, 1H), 6.97 (t, $J = 9.1$ Hz, 2H). $^{13}\text{C NMR (126 MHz, CDCl}_3)$ δ 164.5, 164.0, 145.6, 139.5, 130.3, 129.9, 129.5, 128.9, 128.5, 125.3, 121.4, 118.1. $^{11}\text{B NMR (160 MHz, CDCl}_3)$ δ 28.52 (s). **HRMS (EI)** calcd for $\text{C}_{17}\text{H}_{13}\text{BN}_2\text{O}$: 272.1121, found: 272.1123

4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-phenoxyphenyl)isoxazole (**4c**)




White solid, mp: 200-201 °C. Yield: 65%. $R_f = 0.2$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR (500 MHz, CDCl}_3)$ δ 8.75 – 8.68 (m, 1H), 8.08 (d, $J = 11.6$ Hz, 1H), 7.85 (s, 1H), 7.71 – 7.66

(m, 2H), 7.64 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.45 – 7.36 (m, 3H), 7.24 – 7.14 (m, 2H), 7.14 – 7.09 (m, 3H), 7.07 (d, $J = 8.3$ Hz, 1H), 6.96 (dd, $J = 11.4, 1.8$ Hz, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 163.9, 163.8, 159.0, 156.3, 145.7, 139.5, 130.4, 129.9, 129.5, 128.6, 125.3, 124.8, 124.0, 121.5, 119.5, 118.6, 118.1. ^{11}B NMR (160 MHz, CDCl_3) δ 28.58 (s). HRMS (EI) calcd for $\text{C}_{23}\text{H}_{17}\text{BN}_2\text{O}_2$: 364.1383, found: 364.1384


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4d)



White solid, mp: 215-216 °C. Yield: 70%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

^1H NMR (500 MHz, CDCl_3) δ 8.7 (s, 1H), 8.07 (d, $J = 11.5$ Hz, 1H), 7.82 (s, 1H), 7.62 (dd, $J = 12.6, 7.7$ Hz, 3H), 7.38 (t, $J = 7.6$ Hz, 1H), 7.31 (d, $J = 7.7$ Hz, 2H), 7.19 (t, $J = 7.5$ Hz, 1H), 6.99 (dd, $J = 18.9, 9.8$ Hz, 2H), 2.46 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 164.4, 164.0, 145.5, 139.9, 139.5, 129.6, 129.5, 128.7, 128.5, 127.3, 125.3, 121.4, 118.1, 21.4. ^{11}B NMR (160 MHz, CDCl_3) δ 28.4 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{15}\text{BN}_2\text{O}$: 286.1277, found: 286.1280


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphthalen-2-yl)isoxazole (4e)



White solid, mp: 92-94 °C. Yield: 79%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

^1H NMR (500 MHz, CDCl_3) δ 8.78 (s, 1H), 8.25 (d, $J = 1.5$ Hz, 1H), 8.07 (d, $J = 11.5$ Hz, 1H), 7.95 (dd, $J = 17.3, 8.2$ Hz, 2H), 7.90 (s, 1H), 7.87 (d, $J = 8.0$ Hz, 1H), 7.81 (dd, $J = 8.4, 1.8$ Hz, 1H), 7.63 (d, $J = 7.7$ Hz, 1H), 7.61 – 7.53 (m, 1H), 7.37 – 7.29 (m, 1H), 7.18 (t, $J = 7.5$ Hz, 1H), 7.07 – 6.87 (m, 2H). ^{13}C NMR (126 MHz, CDCl_3) δ 164.4, 164.1, 145.6, 139.5, 133.8, 133.1, 129.4, 128.6, 128.5, 128.5, 128.4, 127.8, 127.6, 127.1, 126.8, 125.9, 125.3, 121.4, 118.1. ^{11}B NMR (160 MHz, CDCl_3) δ 27.6 (s). HRMS (EI) calcd for $\text{C}_{21}\text{H}_{15}\text{BN}_2\text{O}$: 322.1277, found: 322.1277


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-iodophenyl)isoxazole (4f)



White solid, mp: 116-117 °C. Yield: 68%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR (500 MHz, CDCl_3) δ 8.73 (s, 1H), 8.14 (d, $J = 2.2$ Hz, 1H), 8.08 (d, $J = 11.5$ Hz, 1H), 7.86 (d, $J = 8.2$ Hz, 1H), 7.83 (s, 1H), 7.65 (d, $J = 7.9$ Hz, 2H), 7.42 (t, $J = 7.7$ Hz, 1H), 7.21 (t, $J = 7.7$ Hz, 2H), 7.10 (d, $J = 8.2$ Hz, 1H), 6.92 (dd, $J = 11.5, 2.1$ Hz, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 163.8, 162.8, 145.5, 139.2, 138.5, 137.2, 132.0, 130.1, 129.3, 128.4, 127.8, 125.1, 121.3, 117.9, 94.2. ^{11}B NMR (160 MHz, CDCl_3) δ 30.5 (s). HRMS (EI) calcd for $\text{C}_{17}\text{H}_{12}\text{BIN}_2\text{O}$: 398.0087, found: 398.0078


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-bromophenyl)isoxazole (4g)



White solid, mp: 97-98 °C. Yield: 80%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.73 (s, 1H), 8.08 (d, $J = 11.5$ Hz, 1H), 7.93 (s, 1H), 7.84 (s, 1H), 7.72 – 7.56 (m, 3H), 7.42 (t, $J = 7.7$ Hz, 1H), 7.35 (t, $J = 7.9$ Hz, 1H), 7.21 (t, $J = 7.5$ Hz, 1H), 7.09 (d, $J = 8.2$ Hz, 1H), 6.92 (d, $J = 11.5$ Hz, 1H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 163.95, 163.19, 145.8, 139.5, 132.8, 132.3, 131.7, 130.3, 129.5, 128.7, 127.4, 125.4, 122.9, 121.6, 118.2. $^{11}\text{B NMR}$ (160 MHz, CDCl_3) δ 30.1 (s). **HRMS (EI)** calcd for $\text{C}_{17}\text{H}_{12}\text{BBrN}_2\text{O}$: 350.0226, found: 350.0229


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole (4h)



White solid, mp: 83-84 °C. Yield: 79%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.72 (s, 1H), 8.08 (d, $J = 11.5$ Hz, 1H), 7.83 (s, 1H), 7.65 (d, $J = 7.8$ Hz, 1H), 7.54 – 7.35 (m, 4H), 7.22 (q, $J = 7.4$ Hz, 2H), 7.08 (d, $J = 8.2$ Hz, 1H), 6.93 (d, $J = 11.5$ Hz, 1H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 163.8, 163.4, 161.8, 145.8, 139.5, 132.3 (d, $J = 8.4$ Hz), 130.5 (d, $J = 8.2$ Hz), 129.5, 128.7, 125.4, 124.6, 121.6, 118.2, 116.8 (d, $J = 21.4$ Hz), 115.9 (d, $J = 22.9$ Hz). $^{11}\text{B NMR}$ (160 MHz, CDCl_3) δ 30.4 (s). $^{19}\text{F NMR}$ (471 MHz, CDCl_3) δ -111.51 (s). **HRMS (EI)** calcd for $\text{C}_{17}\text{H}_{12}\text{BFN}_2\text{O}$: 290.1027, found: 290.1028


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(2-bromo-4-chlorophenyl)isoxazole (4i)



White solid, mp: 136-138 °C. Yield: 75%. $R_f = 0.3$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR NMR}$ (500 MHz, CDCl_3) δ 8.83 (s, 1H), 8.01 (d, $J = 11.5$ Hz, 1H), 7.78 (d, $J = 1.3$ Hz, 1H), 7.68 – 7.54 (m, 2H), 7.48 (d, $J = 1.5$ Hz, 2H), 7.43 – 7.35 (m, 1H), 7.18 (t, $J = 7.4$ Hz, 1H), 7.01 (d, $J = 8.1$ Hz, 1H), 6.76 (dd, $J = 11.5, 2.0$ Hz, 1H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 163.4, 163.2, 145.8, 139.4, 136.5, 133.0, 132.3, 130.5, 129.5, 128.6, 128.0, 125.3, 123.9, 121.5, 118.1. $^{11}\text{B NMR}$ (160 MHz, CDCl_3) δ 27.6 (s). **HRMS (EI)** calcd for $\text{C}_{17}\text{H}_{11}\text{BBrClN}_2\text{O}$: 383.9836, found: 383.9836


methyl 4-(4-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazol-3-yl)benzoate (4j)



White solid, mp: 151-153 °C. Yield: 80%. $R_f = 0.2$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.72 (s, 1H), 8.14 (d, $J = 8.0$ Hz, 2H), 8.07 (d, $J = 11.5$ Hz, 1H), 7.88 (s, 1H), 7.79 (d, $J = 8.0$ Hz, 2H), 7.64 (d, $J = 7.8$ Hz, 1H), 7.40 (t, $J = 7.7$ Hz, 1H), 7.21 (t, $J = 7.4$ Hz, 1H), 7.08 (d, $J = 8.1$ Hz, 1H), 6.94 – 6.84 (m, 1H), 3.96 (s, 3H). **^{13}C NMR (101 MHz, CDCl_3)** δ 166.5, 163.7, 163.6, 145.8, 139.5, 134.6, 131.2, 130.0, 129.5, 128.8, 128.6, 125.3, 121.6, 118.2, 52.3. **^{11}B NMR (160 MHz, CDCl_3)** δ 28.4 (s). **HRMS (EI)** calcd for $\text{C}_{19}\text{H}_{15}\text{BN}_2\text{O}_3$: 330.1176, found: 330.1181


4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-styrylisoxazole (4k)



White solid, mp: 96-97 °C. Yield: 75%. $R_f = 0.2$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.58 (s, 1H), 8.18 (d, $J = 11.0$ Hz, 2H), 7.72 (d, $J = 7.8$ Hz, 1H), 7.50 (dd, $J = 15.5, 8.4$ Hz, 3H), 7.46 – 7.30 (m, 5H), 7.30 – 7.22 (m, 2H), 7.11 (d, $J = 11.4$ Hz, 1H). **^{13}C NMR (126 MHz, CDCl_3)** δ 162.3, 162.1, 145.9, 139.7, 136.6, 136.0, 129.6, 128.8, 128.8, 128.8, 127.0, 125.5, 121.6, 118.2, 116.2, 77.3, 77.0, 76.8. **^{11}B NMR (160 MHz, CDCl_3)** δ 28.6 (s). **HRMS (EI)** calcd for $\text{C}_{19}\text{H}_{15}\text{BN}_2\text{O}$: 298.1277, found: 298.1279


4-(6-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4l)



White solid, mp: 94-95 °C. Yield: 95%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.70 (s, 1H), 8.00 (d, $J = 11.5$ Hz, 1H), 7.78 (s, 1H), 7.64 – 7.56 (m, 2H), 7.42 (d, $J = 2.0$ Hz, 1H), 7.30 (d, $J = 7.9$ Hz, 2H), 7.21 (dd, $J = 8.3, 2.0$ Hz, 1H), 6.97 – 6.89 (m, 2H), 2.46 (s, 3H), 2.42 (s, 3H). **^{13}C NMR (126 MHz, CDCl_3)** δ 164.4, 163.8, 145.3, 139.9, 137.6, 130.7, 129.8, 129.5, 129.1, 128.7, 127.3, 125.3, 117.9, 21.4, 20.8. **^{11}B NMR (160 MHz, CDCl_3)** δ 28.0 (s). **HRMS (EI)** calcd for $\text{C}_{19}\text{H}_{17}\text{BN}_2\text{O}$: 300.1434, found: 300.1438

4-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4m)




White solid, mp: 105-106 °C. Yield: 83%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.71 (s, 1H), 7.98 (d, $J = 11.5$ Hz, 1H), 7.87 (s, 1H), 7.58 (d, $J = 7.9$ Hz, 2H), 7.35 – 7.26 (m, 3H), 7.15 – 7.09 (m, 1H), 7.04 – 6.94 (m, 2H), 2.46 (s, 3H). **^{13}C NMR (101 MHz, CDCl_3)** δ 164.4, 163.9, 157.3 (d, $J = 239.9$ Hz), 144.6 (d, $J = 3.3$ Hz), 140.0, 136.0, 129.6, 128.6, 127.2, 125.7 (d, $J = 8.1$ Hz), 119.3 (d, $J = 8.2$ Hz), 116.5 (d, $J = 24.6$ Hz), 113.8 (d, $J = 21.5$ Hz), 21.4. **^{11}B NMR (160 MHz,**

CDCl_3) δ 28.2 (s). ^{19}F NMR (471 MHz, CDCl_3) δ -123.91 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{14}\text{BFN}_2\text{O}$: 304.1183, found: 304.1186


4-(6-bromobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4n)



White solid, mp: 114-115 °C. Yield: 76%. R_f = 0.3 (silica gel, PE:EtOAc = 10:1)

^1H NMR (500 MHz, CDCl_3) δ 8.70 (s, 1H), 7.94 (d, J = 11.6 Hz, 1H), 7.84 (s, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.65 – 7.58 (m, 2H), 7.44 (dd, J = 8.5, 2.2 Hz, 1H), 7.06 – 6.96 (m, 3H), 6.91 (d, J = 8.6 Hz, 1H), 3.88 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 164.0, 160.9, 144.3, 138.3, 131.5, 131.3, 130.1, 126.7, 122.2, 119.7, 114.3, 113.8, 55.4. ^{11}B NMR (160 MHz, CDCl_3) δ 28.5 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{14}\text{BBrN}_2\text{O}_2$: 380.0332, found: 380.0332


4-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4o)



White solid, mp: 118-120 °C. Yield: 84%. R_f = 0.4 (silica gel, PE:EtOAc = 10:1)

^1H NMR (500 MHz, CDCl_3) δ 8.79 (s, 1H), 8.06 (s, 1H), 7.93 (dd, J = 11.8, 1.7 Hz, 1H), 7.56 (d, J = 7.8 Hz, 2H), 7.39 (s, 1H), 7.33 (d, J = 7.8 Hz, 2H), 7.16 (dd, J = 10.3, 2.2 Hz, 1H), 7.08 (dd, J = 11.7, 2.0 Hz, 1H), 2.46 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 164.5, 152.3, 150.4, 143.6 (d, J = 3.3 Hz), 140.1, 129.8, 128.6, 127.0, 127.2 (d, J = 3.8 Hz), 127.3 (d, J = 13.9 Hz), 125.2 (d, J = 9.8 Hz), 123.9 (d, J = 3.6 Hz), 114.0 (d, J = 21.6 Hz), 21.4. ^{11}B NMR (160 MHz, CDCl_3) δ 28.3 (s). ^{19}F NMR (471 MHz, CDCl_3) δ -134.41 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{13}\text{BClFN}_2\text{O}$: 338.0793, found: 338.0797


4-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4p)



White solid, mp: 106-107 °C. Yield: 90%. R_f = 0.5 (silica gel, PE:EtOAc = 10:1)

^1H NMR (500 MHz, CDCl_3) δ 8.73 (s, 1H), 8.01 (d, J = 11.6 Hz, 1H), 7.83 (s, 1H), 7.57 (dd, J = 8.1, 5.4 Hz, 3H), 7.31 (d, J = 7.8 Hz, 2H), 6.99 – 6.82 (m, 2H), 6.69 (dd, J = 9.9, 2.5 Hz, 1H), 2.46 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 164.3 (d, J = 21.5 Hz), 163.8, 161.3, 145.0, 140.7 (d, J = 11.1 Hz), 140.1, 131.1 (d, J = 10.0 Hz), 129.6, 128.7, 127.1, 122.0, 109.8 (d, J = 23.2 Hz), 104.0 (d, J = 24.1 Hz), 21.4. ^{11}B NMR (160 MHz, CDCl_3) δ 28.8 (s). ^{19}F NMR (471 MHz, CDCl_3) δ -111.45 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{14}\text{BFN}_2\text{O}$: 304.1183, found: 304.1185


3-(p-tolyl)-4-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4q)



White solid, mp: 86-87 °C. Yield: 82%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.73 (s, 1H), 8.01 (d, $J = 11.6$ Hz, 1H), 7.91 (s, 1H), 7.61 – 7.55 (m, 2H), 7.48 (d, $J = 2.4$ Hz, 1H), 7.31 (d, $J = 7.8$ Hz, 2H), 7.28 – 7.21 (m, 1H), 7.07 – 6.98 (m, 2H), 2.46 (s, 3H). **^{13}C NMR (101 MHz, CDCl_3)** δ 164.4, 164.2, 144.7, 143.1, 140.1, 138.0, 129.6, 128.7, 127.1, 125.5, 122.0, 121.1, 119.3, 21.41. **^{11}B NMR (160 MHz, CDCl_3)** δ 28.6 (s). **^{19}F NMR (471 MHz, CDCl_3)** δ -60.14 (s). **HRMS (EI)** calcd for $\text{C}_{19}\text{H}_{14}\text{BF}_3\text{N}_2\text{O}_2$: 370.1100, found: 370.1105


4-(4-phenylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4r)



White solid, mp: 157-159 °C. Yield: 90%. $R_f = 0.4$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.74 (s, 1H), 7.86 (s, 1H), 7.71 – 7.63 (m, 2H), 7.63 – 7.59 (m, 1H), 7.52 – 7.46 (m, 2H), 7.46 – 7.42 (m, 3H), 7.41 – 7.36 (m, 1H), 7.34 (d, $J = 7.9$ Hz, 2H), 7.15 – 7.08 (m, 1H), 7.05 (d, $J = 8.1$ Hz, 1H), 6.91 (d, $J = 2.0$ Hz, 1H), 2.48 (s, 3H). **^{13}C NMR (126 MHz, CDCl_3)** δ 164.4, 164.2, 156.9, 142.12, 140.1, 140.0, 129.6, 128.9, 128.7, 128.45, 128.2, 127.5, 127.3, 124.4, 121.2, 118.6, 21.4. **^{11}B NMR (160 MHz, CDCl_3)** δ 27.8 (s). **HRMS (EI)** calcd for $\text{C}_{24}\text{H}_{19}\text{BN}_2\text{O}$: 362.1590, found: 362.1592


3-(4-methoxyphenyl)-4-(4-methylbenzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4s)



White solid, mp: 115-116 °C. Yield: 95%. $R_f = 0.3$ (silica gel, PE:EtOAc = 10:1)

^1H NMR NMR (500 MHz, CDCl_3) δ 8.68 (s, 1H), 7.82 (d, $J = 8.1$ Hz, 1H), 7.70 (s, 1H), 7.65 (d, $J = 8.4$ Hz, 2H), 7.39 (t, $J = 7.7$ Hz, 1H), 7.21 (t, $J = 7.6$ Hz, 1H), 7.02 (dd, $J = 8.3, 4.6$ Hz, 3H), 6.81 (s, 1H), 3.89 (s, 3H), 2.61 (s, 3H). **^{13}C NMR (101 MHz, CDCl_3)** δ 164.0, 163.7, 160.7, 152.0, 139.8, 130.1, 128.2, 125.7, 125.3, 122.5, 121.3, 118.7, 114.2, 55.3, 22.9. **^{11}B NMR (160 MHz, CDCl_3)** δ 28.2 (s). **HRMS (EI)** calcd for $\text{C}_{19}\text{H}_{17}\text{BN}_2\text{O}_2$: 316.1383, found: 316.1385


4-(1-benzylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4t)



White solid, mp: 133-135 °C. Yield: 92%. $R_f = 0.2$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.15 (s, 1H), 8.07 (d, $J = 11.4$ Hz, 1H), 7.75 (d, $J = 7.8$ Hz, 1H), 7.59 (d, $J = 8.5$ Hz, 2H), 7.41 (d, $J = 4.0$ Hz, 2H), 7.35 – 7.21 (m, 4H), 7.04 (d, $J = 7.4$ Hz, 2H), 6.88 (d, $J = 8.4$ Hz, 2H), 6.81 (d, $J = 11.5$ Hz, 1H), 5.40 (s, 2H), 3.83 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 163.8, 160.5, 160.1, 145.3, 141.2, 138.2, 130.4, 129.6, 128.8, 128.8, 127.3, 127.1, 125.4, 122.4, 121.5, 116.8, 114.0, 55.2, 52.5. $^{11}\text{B NMR}$ (160 MHz, CDCl_3) δ 32.2 (s). HRMS (EI) calcd for $\text{C}_{25}\text{H}_{21}\text{BN}_2\text{O}_2$: 392.1696, found: 392.1702

4-(dibenzo[c,e][1,2]azaborinin-6(5H)-yl)-3-(4-methoxyphenyl)isoxazole (7)




White solid, mp: 167-169 °C. Yield: 80%. $R_f = 0.3$ (silica gel, PE:EtOAc = 10:1)

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.59 (s, 1H), 8.49 (dd, $J = 22.9, 8.2$ Hz, 2H), 8.00 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.81 – 7.74 (m, 1H), 7.66 (s, 1H), 7.64 – 7.59 (m, 2H), 7.50 – 7.40 (m, 2H), 7.36 – 7.29 (m, 1H), 7.13 (dd, $J = 7.9, 1.3$ Hz, 1H), 6.88 – 6.79 (m, 2H), 3.77 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 164.0, 162.3, 160.6, 138.8, 138.2, 135.7, 131.5, 129.8, 128.2, 126.4, 123.9, 123.4, 122.3, 122.1, 122.0, 119.2, 114.1, 55.2. $^{11}\text{B NMR}$ (160 MHz, CDCl_3) δ 32.1 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{14}\text{BBrN}_2\text{O}_2$: 380.0332, found: 380.0332

5. Synthetic transformations

5-(3-iodobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (8)




In air, a 100 mL schlenk flask was charged with **3e** (1.5 mmol, 1 equiv), NIS (1.8 mmol, 1.2 equiv) and AgOTf (10 mol%). The flask was evacuated and filled with argon for three cycles. 15 mL of dry DCM was added under argon. The reaction was allowed to stir at room temperature for 12 h. Upon completion, after removal of the solvent, the crude reaction mixture was purified on column chromatography (petroleum ether and ethyl acetate) to afford the desired product **8**.

White solid, mp: 178 – 180 °C. Yield: 82%. $R_f = 0.5$ (silica gel, PE:EtOAc = 10:1).

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.85 (s, 1H), 8.78 (s, 1H), 7.84 (s, 1H), 7.76 (s, 1H), 7.72 (d, $J = 7.7$ Hz, 1H), 7.61 (d, $J = 7.9$ Hz, 1H), 7.58 – 7.52 (m, 1H), 7.45 – 7.36 (m, 2H), 7.31 – 7.25 (m, 2H), 2.46 (s, 3H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 161.9, 155.1, 138.7, 138.6, 130.6, 129.6, 128.8, 128.7, 128.6, 127.6, 126.3, 124.2,

122.4, 118.6, 112.4, 21.4. ^{11}B NMR (160 MHz, CDCl_3) δ 26.9 (s). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{14}\text{BIN}_2\text{O}$: 412.0244, found: 412.0239

5-(3-((3-methoxyphenyl)ethynyl)benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (9)




In air, a 25 mL schlenk tube was charged with **8** (0.2 mmol, 1 equiv), CuI (5 mol%) and $\text{PdCl}_2(\text{PPh}_3)_2$ (5 mol%). The flask was evacuated and filled with argon for three cycles. 1.35 mL Et_3N , 0.65 mL THF and 3-ethynylanisole (0.6 mmol, 3 equiv) was added under argon. The reaction was allowed to stir at room temperature for 12 h. Upon completion, after removal of the solvent, the crude reaction mixture was purified on column chromatography (petroleum ether and ethyl acetate) to afford the desired product **9**.

White solid, mp: 169 – 170 °C. Yield: 81%. R_f = 0.3 (silica gel, PE:EtOAc = 10:1).

^1H NMR (500 MHz, CDCl_3) δ 8.85 (s, 1H), 8.39 (s, 1H), 7.81 (s, 1H), 7.72 (s, 1H), 7.68 (dd, J = 13.1, 7.7 Hz, 2H), 7.51 (t, J = 7.6 Hz, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.38 – 7.30 (m, 2H), 7.27 (d, J = 6.9 Hz, 2H), 7.22 (d, J = 7.5 Hz, 1H), 7.15 (s, 1H), 6.99 – 6.90 (m, 1H), 3.83 (s, 3H), 2.42 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 162.1, 159.5, 149.6, 138.8, 138.6, 130.6, 129.9, 129.7, 129.6, 129.1, 128.8, 127.6, 125.0, 124.9, 124.1, 123.9, 122.5, 118.5, 116.1, 114.8, 112.9, 94.6, 91.8, 55.2, 21.3. ^{11}B NMR (160 MHz, CDCl_3) δ 26.1 (s). HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{22}\text{BN}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$: 417.1774, found: 417.1777

5-(3-(3-methoxyphenyl)benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (10)




In glove box, a 25 mL schlenk tube was charged with ZnCl_2 (0.32 mmol, 1.6 equiv), 3-Methoxymagnesium bromide (1.0M in THF; 0.32 mL, 0.32 mmol, 1.6 equiv) and 1 mL THF. The reaction was allowed to stir at room temperature for 20 min. Then, **8** (0.2 mmol, 1 equiv), NMI (1.2 equiv), $\text{Pd}_2(\text{dba})_3$ (2 mol%), PCy_3 (8 mol%) and 1 mL NMP were added to the tube. The reaction was allowed to stir at room temperature for 16 h. Upon completion, after removal of the solvent, the crude reaction mixture was purified on column chromatography (petroleum ether and ethyl acetate) to afford the desired product **10**.

White solid, mp: 99 – 101 °C. Yield: 80%. R_f = 0.5 (silica gel, PE:EtOAc = 10:1).

^1H NMR (500 MHz, CDCl_3) δ 8.94 (s, 1H), 8.08 (s, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.61 (s, 1H), 7.57 – 7.44 (m, 3H), 7.38 (t, J = 7.9 Hz, 1H), 7.35 – 7.27 (m, 2H), 7.24 (t, J = 7.9 Hz, 1H), 7.06 (d, J = 7.6 Hz, 1H), 7.03 (t, J = 2.1 Hz, 1H), 6.97 (dd, J = 8.1, 2.6 Hz, 1H), 6.61 (s, 1H), 3.86 (s, 3H), 2.40 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 161.9, 159.5, 145.2, 144.7, 138.8, 138.5, 130.5, 129.7, 129.0, 129.1, 128.9, 128.7, 127.5, 125.3, 124.1, 122.3, 121.1, 118.3, 113.8, 112.5, 112.1, 55.3, 21.3. ^{11}B NMR (160 MHz, CDCl_3) δ 27.0 (s). HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{22}\text{BN}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$: 393.1774, found: 393.1777

ethyl 4-(2-(3-(*m*-tolyl)isoxazol-5-yl)-1,2-dihydrobenzo[*e*][1,2]azaborinin-3-yl)butanoate (**11**)




In air, a 25 mL schlenk tube was charged with **8** (0.2 mmol, 1 equiv), Mn (0.4 mmol, 2 equiv), NaBF₄ (0.1 mmol, 0.5 equiv), NiCl₂.glyme (10 mol%), 4,4'-Dimethyl-2,2'-bipyridyl (10 mol%). The tube was evacuated and filled with argon for three cycles. 1.5 mL Cyclohexane, 0.5 mL DMA and ethyl 4-Iodobutyrate (0.24 mmol, 1.2 equiv) was added under argon. The reaction was allowed to stir at 40 °C for 16 h. Upon completion, after removal of the solvent, the crude reaction mixture was purified on column chromatography (petroleum ether and ethyl acetate) to afford the desired product **11**.

White solid, mp: 70 – 72 °C. Yield: 85%. R_f = 0.4 (silica gel, PE:EtOAc = 10:1).

¹H NMR (500 MHz, CDCl₃) δ 8.77 (s, 1H), 7.92 (s, 1H), 7.81 (s, 1H), 7.76 (d, *J* = 7.6 Hz, 1H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.45 (t, *J* = 7.5 Hz, 1H), 7.42 – 7.33 (m, 3H), 7.32 – 7.19 (m, 2H), 4.16 (q, *J* = 7.1 Hz, 2H), 2.92 (t, *J* = 7.9 Hz, 2H), 2.56 – 2.32 (m, 5H), 2.11 – 1.89 (m, 2H), 1.26 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 173.7, 162.2, 144.1, 138.6, 138.4, 130.5, 129.1, 128.9, 128.8, 128.2, 127.7, 125.5, 124.1, 121.9, 118.1, 111.2, 60.3, 34.9, 33.8, 26.2, 21.4, 14.2. ¹¹B NMR (160 MHz, CDCl₃) δ 27.6 (s). HRMS (EI) calcd for C₂₄H₂₅BN₂O₃: 400.1958, found: 400.1965

5-(benzo[*e*][1,2]azaborinin-2(1H)-yl)-N-ethylisoxazole-3-carboxamide (**12**)




In air, a 25 mL schlenk tube was charged with 3t (0.1 mmol, 1 equiv) and LiBr (10 mol%). The tube was evacuated and filled with argon for three cycles. Ethylamine (2.0 M in THF; 0.5 mL, 1 mmol, 10 equiv) and 1 mL THF was added under argon. The reaction was allowed to stir at room temperature for 12 h. Upon completion, after removal of the solvent, the crude reaction mixture was purified on column chromatography (petroleum ether and ethyl acetate) to afford the desired product **12**.


White solid, mp: 204 - 206 °C. Yield: 90%. R_f = 0.3 (silica gel, PE:EtOAc = 5:1).

¹H NMR (500 MHz, CDCl₃) δ 8.68 (s, 1H), 8.22 (d, *J* = 11.5 Hz, 1H), 7.70 (dd, *J* = 7.8, 1.3 Hz, 1H), 7.54 – 7.47 (m, 1H), 7.43 (d, *J* = 8.0 Hz, 1H), 7.35, 7.30 – 7.24 (m, 1H), 7.18 (dd, *J* = 11.4, 1.9 Hz, 1H), 6.92 (s, 1H), 3.61 – 3.39 (m, 2H), 1.27 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 159.1, 158.2, 147.2, 139.2, 129.8, 129.1, 126.1, 122.1, 118.6, 112.1, 34.5, 14.7. ¹¹B NMR (160 MHz, CDCl₃) δ 27.1 (s). HRMS (ESI) calcd for C₁₄H₁₅BN₃O₂ [M+H]⁺: 268.1257, found: 268.1260

6. Crystal structure of compound 3a and 4i



3a
(CCDC 2202557)



Bond precision: C-C = 0.0049 Å Wavelength=0.71073

Cell: a=5.822(4) b=9.698(8) c=17.608(14)
alpha=84.39(4) beta=83.54(4) gamma=49.04(3)

Temperature: 296 K

	Calculated	Reported
Volume	745.6(11)	745.7(10)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C ₁₈ H ₁₆ B N ₂ O ₂	C ₁₈ H ₁₆ B N ₂ O ₂
Sum formula	C ₁₈ H ₁₆ B N ₂ O ₂	C ₁₈ H ₁₆ B N ₂ O ₂
Mr	303.14	303.14
D _x , g cm ⁻³	1.350	1.350

Z	2	2
Mu (mm-1)	0.088	0.088
F000	318.0	318.0
F000'	318.13	
h,k,lmax	6,11,20	6,11,20
Nref	2626	2614
Tmin,Tmax	0.987,0.989	0.623,0.747
Tmin'	0.987	

Correction method= # Reported T Limits: Tmin=0.623 Tmax=0.747 AbsCorr =
MULTI-SCAN

Data completeness= 0.995



Theta(max)= 25.022

R(reflections)= 0.0658(1564)

wR2(reflections)= 0.1873(2614)

S = 1.028

Npar= 209



Bond precision: C-C = 0.0061 Å Wavelength=0.71073

Cell: a=9.0910(6) b=17.1679(11) c=10.8642(7)
alpha=90 beta=105.897(2) gamma=90

Temperature: 296 K

	Calculated	Reported
Volume	1630.77(18)	1630.76(18)
Space group	P 21/n	P 21/n
Hall group	-P 2yn	-P 2yn
Moiety formula	C17 H11 B Br Cl N2 O	?
Sum formula	C17 H11 B Br Cl N2 O	C17 H11 B Br Cl N2 O
Mr	385.44	385.45
Dx,g cm ⁻³	1.570	1.570
Z	4	4
Mu (mm ⁻¹)	2.688	2.688
F000	768.0	768.0


F000'	767.69	
h,k,lmax	10,20,12	10,20,12
Nref	2861	2860
Tmin,Tmax		
Tmin'		
Correction method=	Not given	
Data completeness=	1.000	Theta(max)= 24.999
R(reflections)=	0.0519(2353)	wR2(reflections)= 0.1345(2860)
S =	1.091	Npar= 209

7. References


- (1) I. Valencia, P. García-García, D. Sucunza, F. Mendicuti and J. J. Vaquero, 1,10a-Dihydro-1-aza-10a-boraphenanthrene and 6a,7-Dihydro-7-aza-6a-boratetraphene: Two New Fluorescent BN-PAHs, *J. Org. Chem.*, 2021, **86**, 16259-16267.
- (2) J. Yang, J.-W. Zhang, W. Bao, S.-Q. Qiu, S. Li, S.-H. Xiang, J. Song, J. Zhang and B. Tan, Chiral Phosphoric Acid-Catalyzed Remote Control of Axial Chirality at Boron–Carbon Bond, *J. Am. Chem. Soc.*, 2021, **143**, 12924-12929.
- (3) R. J. B. Schäfer, M. R. Monaco, M. Li, A. Tirla, P. Rivera-Fuentes and H. Wennemers, The Bioorthogonal Isonitrile–Chlorooxime Ligation, *J. Am. Chem. Soc.*, 2019, **141**, 18644-18648.
- (4) K. Yang, F. Zhang, T. Fang, G. Zhang and Q. Song, Stereospecific 1,4-metallate shift enables stereoconvergent synthesis of ketoximes. *Angew. Chem., Int. Ed.*, 2019, **58**, 13421–13426.
- (5) A. L. Rousseau, S. R. Buddoo, G. E. R. Gordon, S. Beemadu, B. G. Kupi, M. J. Lepuru, M. C. Maumela, A. Parsoo, D. M. Sibiyi and D. Brady, Scale-Up of a Chemo-Biocatalytic Route to (2R,4R)- and (2S,4S)-Monatin, *Org. Process Res. Dev.*, 2011, **15**, 249-257.

8. NMR Spectra


2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1a)




2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1a)




2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1a)




2-ethynyl-6-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1b)




2-ethynyl-6-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1b)




2-ethynyl-6-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1b)




2-ethynyl-6-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1b)




2-ethynyl-6-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1c)




2-ethynyl-6-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1c)




2-ethynyl-6-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1c)




2-ethynyl-5-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1d)




2-ethynyl-5-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1d)




2-ethynyl-5-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1d)




6-chloro-2-ethynyl-8-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1e)




6-chloro-2-ethynyl-8-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1e)




6-chloro-2-ethynyl-8-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1e)




6-chloro-2-ethynyl-8-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1e)




2-ethynyl-6-methoxy-1,2-dihydrobenzo[e][1,2]azaborinine (1f)




2-ethynyl-6-methoxy-1,2-dihydrobenzo[e][1,2]azaborinine (1f)




2-ethynyl-6-methoxy-1,2-dihydrobenzo[e][1,2]azaborinine (1f)




2-ethynyl-7-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1g)




2-ethynyl-7-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1g)




2-ethynyl-7-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1g)




2-ethynyl-7-fluoro-1,2-dihydrobenzo[e][1,2]azaborinine (1g)




6-chloro-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1h)




6-chloro-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1h)




6-chloro-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1h)




2-ethynyl-6-(trifluoromethoxy)-1,2-dihydrobenzo[e][1,2]azaborinine (1i)




2-ethynyl-6-(trifluoromethoxy)-1,2-dihydrobenzo[e][1,2]azaborinine (1i)




2-ethynyl-6-(trifluoromethoxy)-1,2-dihydrobenzo[e][1,2]azaborinine (1i)




2-ethynyl-6-(trifluoromethoxy)-1,2-dihydrobenzo[e][1,2]azaborinine (1i)




2-ethynyl-4-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1j)




2-ethynyl-4-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1j)




2-ethynyl-4-methyl-1,2-dihydrobenzo[e][1,2]azaborinine (1j)




6-bromo-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1k)




6-bromo-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1k)




6-bromo-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1k)




2-ethynyl-4-phenyl-1,2-dihydrobenzo[e][1,2]azaborinine (1l)




2-ethynyl-4-phenyl-1,2-dihydrobenzo[e][1,2]azaborinine (11)




2-ethynyl-4-phenyl-1,2-dihydrobenzo[e][1,2]azaborinine (11)




2-ethynyl-1-isopropyl-1,2-dihydrobenzo[e][1,2]azaborinine (1m)




2-ethynyl-1-isopropyl-1,2-dihydrobenzo[e][1,2]azaborinine (1m)




2-ethynyl-1-isopropyl-1,2-dihydrobenzo[e][1,2]azaborinine (1m)




1-benzyl-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1n)




1-benzyl-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1n)




1-benzyl-2-ethynyl-1,2-dihydrobenzo[e][1,2]azaborinine (1n)




2-(hex-1-yn-1-yl)-1,2-dihydrobenzo[e][1,2]azaborinine (1o)




2-(hex-1-yn-1-yl)-1,2-dihydrobenzo[e][1,2]azaborinine (1o)




2-(hex-1-yn-1-yl)-1,2-dihydrobenzo[e][1,2]azaborinine (1o)




6-ethynyl-5,6-dihydrodibenzo[c,e][1,2]azaborinine (5)




6-ethynyl-5,6-dihydrobenzo[c,e][1,2]azaborinine (5)




6-ethynyl-5,6-dihydrobenzo[c,e][1,2]azaborinine (5)




N-hydroxy-4-methoxybenzimidoyl chloride (2a)




N-hydroxybenzimidoyl chloride (2b)




N-hydroxy-4-phenoxybenzimidoyl chloride (2c)




N-hydroxy-4-methylbenzimidoyl chloride (2d)




N-hydroxy-3-methylbenzimidoyl chloride (2e)




N-hydroxy-3,4-dimethylbenzimidoyl chloride (2f)




N-hydroxy-3-(trifluoromethoxy)benzimidoyl chloride (2i)




N-hydroxy-3-iodobenzimidoyl chloride (2j)




3-bromo-N-hydroxybenzimidoyl chloride (2k)




3-fluoro-N-hydroxybenzimidoyl chloride (2l)




2-bromo-4-chloro-N-hydroxybenzimidoyl chloride (2m)




2-bromo-4-chloro-N-hydroxybenzimidoyl chloride (2m)




methyl 4-(chloro(hydroxyimino)methyl)benzoate (2n)




N-hydroxy-1-naphthimidoyl chloride (2o)




N-hydroxy-2-naphthimidoyl chloride (2p)




N-hydroxycinnamimidoyl chloride (2q)




N-hydroxy-3-(4-methoxyphenyl)acrylimidoyl chloride (2r)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3a)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3a)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3a)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenylisoxazole (3b)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenylisoxazole (3b)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenylisoxazole (3b)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-phenoxyphenyl)isoxazole (3c)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-phenoxyphenyl)isoxazole (3c)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-phenoxyphenyl)isoxazole (3c)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3d)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3d)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3d)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3e)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3e)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3e)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3,4-dimethylphenyl)isoxazole (3f)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3,4-dimethylphenyl)isoxazole (3f)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3,4-dimethylphenyl)isoxazole (3f)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-mesitylisoxazole (3g)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-mesitylisoxazole (3g)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-mesitylisoxazole (3g)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole (3h)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole (3h)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole (3h)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-(trifluoromethoxy)phenyl)isoxazole (3i)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-(trifluoromethoxy)phenyl)isoxazole (3i)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-(trifluoromethoxy)phenyl)isoxazole (3i)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-(trifluoromethoxy)phenyl)isoxazole (3i)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-iodophenyl)isoxazole (3j)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-iodophenyl)isoxazole (3j)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-iodophenyl)isoxazole (3j)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-bromophenyl)isoxazole (3k)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-bromophenyl)isoxazole (3k)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-bromophenyl)isoxazole (3k)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole (3l)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole(3I)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole(3I)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole(3l)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(2-bromo-4-chlorophenyl)isoxazole (3m)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(2-bromo-4-chlorophenyl)isoxazole (3m)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(2-bromo-4-chlorophenyl)isoxazole (3m)




methyl 3-(5-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazol-3-yl)benzoate (3n)




methyl 3-(5-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazol-3-yl)benzoate (3n)




methyl 3-(5-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazol-3-yl)benzoate (3n)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphth[6,5-b]furan-1-yl)isoxazole (3o)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphth[6,5-b]furan-1-yl)isoxazole (3o)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphth[6,5-b]furan-1-yl)isoxazole (3o)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphthalen-2-yl)isoxazole (3p)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphthalen-2-yl)isoxazole (3p)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphthalen-2-yl)isoxazole (3p)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-styrylisoxazole (3q)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-styrylisoxazole (3q)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-styrylisoxazole (3q)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxystyryl)isoxazole (3r)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxystyryl)isoxazole (3r)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxystyryl)isoxazole (3r)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenethylisoxazole (3s)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenethylisoxazole (3s)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenethylisoxazole (3s)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-bromoisoxazole (3t)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-bromoisoxazole (3t)




5-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-bromoisoxazole (3t)




ethyl 5-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole-3-carboxylate (3u)




ethyl 5-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole-3-carboxylate (3u)




ethyl 5-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole-3-carboxylate (3u)




5-(6-methoxybenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3v)




5-(6-methoxybenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3v)




5-(6-methoxybenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3v)




5-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3w)




5-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3w)




5-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3w)




5-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3w)




5-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3x)




5-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3x)




5-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3x)




5-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (3x)




3-(4-methoxyphenyl)-5-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (3y)




3-(4-methoxyphenyl)-5-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (3y)




3-(4-methoxyphenyl)-5-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (3y)




3-(4-methoxyphenyl)-5-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (3y)




5-(6-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3z)




5-(6-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3z)




5-(6-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3z)




5-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3aa)




5-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3aa)




5-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3aa)




5-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3aa)




5-(4-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3ab)




5-(4-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3ab)




5-(4-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3ab)




5-(4-phenylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3ac)




5-(4-phenylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3ac)




5-(4-phenylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (3ac)




5-(5-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3ad)




5-(5-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3ad)




5-(5-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3ad)




5-(1-benzylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3ae)




5-(1-benzylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3ae)




5-(1-benzylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (3ae)




5-(1-isopropylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole(3af)




5-(1-isopropylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole(3af)




5-(1-isopropylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole(3af)




5-(dibenzo[c,e][1,2]azaborinin-6(5H)-yl)-3-(p-tolyl)isoxazole (6)




5-(dibenzo[c,e][1,2]azaborinin-6(5H)-yl)-3-(p-tolyl)isoxazole (6)




5-(dibenzo[c,e][1,2]azaborinin-6(5H)-yl)-3-(p-tolyl)isoxazole (6)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4a)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4a)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4a)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenylisoxazole (4b)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenylisoxazole (4b)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-phenylisoxazole (4b)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-phenoxyphenyl)isoxazole(4c)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-phenoxyphenyl)isoxazole(4c)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-phenoxyphenyl)isoxazole (4c)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4d)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4d)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4d)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphthalen-2-yl)isoxazole (4e)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphthalen-2-yl)isoxazole (4e)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(naphthalen-2-yl)isoxazole (4e)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-iodophenyl)isoxazole (4f)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-iodophenyl)isoxazole (4f)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-iodophenyl)isoxazole (4f)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-bromophenyl)isoxazole (4g)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-bromophenyl)isoxazole (4g)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-bromophenyl)isoxazole (4g)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole (4h)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole (4h)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole (4h)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(3-fluorophenyl)isoxazole (4h)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(2-bromo-4-chlorophenyl)isoxazole (4i)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(2-bromo-4-chlorophenyl)isoxazole (4i)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-(2-bromo-4-chlorophenyl)isoxazole (4i)




methyl 4-(4-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazol-3-yl)benzoate (4j)




methyl 4-(4-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazol-3-yl)benzoate (4j)




methyl 4-(4-(benzo[e][1,2]azaborinin-2(1H)-yl)isoxazol-3-yl)benzoate (4j)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-styrylisoxazole (4k)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-styrylisoxazole (4k)




4-(benzo[e][1,2]azaborinin-2(1H)-yl)-3-styrylisoxazole (4k)




4-(6-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4I)




4-(6-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4I)




4-(6-methylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4l)




4-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4m)




4-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4m)




4-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4m)




4-(6-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4m)




4-(6-bromobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4n)




4-(6-bromobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4n)




4-(6-bromobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4n)




4-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4o)




4-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4o)




4-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4o)




4-(6-chloro-8-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4o)




4-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4p)




4-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4p)




4-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4p)




4-(7-fluorobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4p)




3-(p-tolyl)-4-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4q)




3-(p-tolyl)-4-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4q)




3-(p-tolyl)-4-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4q)




3-(p-tolyl)-4-(6-(trifluoromethoxy)benzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4q)




4-(4-phenylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4r)




4-(4-phenylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4r)




4-(4-phenylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(p-tolyl)isoxazole (4r)




3-(4-methoxyphenyl)-4-(4-methylbenzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4s)




3-(4-methoxyphenyl)-4-(4-methylbenzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4s)




3-(4-methoxyphenyl)-4-(4-methylbenzo[e][1,2]azaborinin-2(1H)-yl)isoxazole (4s)




4-(1-benzylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4t)




4-(1-benzylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4t)




4-(1-benzylbenzo[e][1,2]azaborinin-2(1H)-yl)-3-(4-methoxyphenyl)isoxazole (4t)




4-(dibenzo[c,e][1,2]azaborinin-6(5H)-yl)-3-(4-methoxyphenyl)isoxazole (7)




4-(dibenzo[c,e][1,2]azaborinin-6(5H)-yl)-3-(4-methoxyphenyl)isoxazole (7)




4-(dibenzo[c,e][1,2]azaborinin-6(5H)-yl)-3-(4-methoxyphenyl)isoxazole (7)




5-(3-iodobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (8)




5-(3-iodobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (8)




5-(3-iodobenzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (8)




5-(3-((3-methoxyphenyl)ethynyl)benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (9)




5-(3-((3-methoxyphenyl)ethynyl)benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (9)




5-(3-((3-methoxyphenyl)ethynyl)benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (9)




5-(3-(3-methoxyphenyl)benzo[e][1,2]azaborinin-2(1H)-yl)-3-(m-tolyl)isoxazole (10)




ethyl 4-(2-(3-(m-tolyl)isoxazol-5-yl)-1,2-dihydrobenzo[e][1,2]azaborinin-3-yl)butanoate (11)




ethyl 4-(2-(3-(m-tolyl)isoxazol-5-yl)-1,2-dihydrobenzo[e][1,2]azaborinin-3-yl)butanoate (11)




ethyl 4-(2-(3-(m-tolyl)isoxazol-5-yl)-1,2-dihydrobenzo[e][1,2]azaborinin-3-yl)butanoate (11)



5-(benzo[e][1,2]azaborinin-2(1H)-yl)-N-ethylisoxazole-3-carboxamide (12)



5-(benzo[e][1,2]azaborinin-2(1H)-yl)-N-ethylisoxazole-3-carboxamide (12)



5-(benzo[e][1,2]azaborinin-2(1H)-yl)-N-ethylisoxazole-3-carboxamide (12)

